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The	  main	  goal	  of	  this	  project	  was	  to	  test	  the	  effectiveness	  of	  a	  novel	  combination	  
neuroprotection	  therapy	  for	  traumatic	  brain	  injury	  (TBI).	  TBI	  affects	  millions	  of	  people	  
worldwide	  every	  year.	  Neuroinflammation,	  excitotoxicity	  and	  neuronal	  death	  as	  well	  as	  
related	  mechanisms	  contribute	  to	  the	  development	  of	  acute	  and	  complex	  neurological	  
deficits,	  including	  post-­‐traumatic	  seizures	  and	  cognitive	  dysfunction.	  Neuroprotection	  
approaches	  targeting	  acute	  and	  chronic	  phases	  of	  TBI	  are	  needed	  to	  limit	  the	  damage	  
and	  prevent	  post-­‐TBI	  dysfunction.	  A	  variety	  of	  neuroprotection	  approaches	  such	  as	  
statins,	  progesterone	  (P),	  cyclosporine	  A	  and	  anti-­‐inflammatory	  agents	  have	  been	  
tested	  that	  either	  target	  neurons	  or	  non-­‐neuronal	  cells	  in	  animal	  models	  of	  TBI.	  Herein	  
we	  evaluated	  the	  neuroprotective	  potential	  of	  the	  neurosteroid	  Ganaxolone	  (GX)	  in	  a	  
mouse	  TBI	  model.	  	  GX	  is	  a	  synthetic	  neurosteroid	  related	  to	  allopregnanolone	  that	  has	  
sedative,	  anxiolytic,	  and	  anticonvulsant	  effects.	  To	  our	  knowledge	  GX	  has	  not	  been	  
used	  as	  a	  neuroprotective	  agent	  for	  TBI.	  	  We	  utilized	  a	  controlled	  cortical	  impact	  (CCI)	  
model,	  which	  simulates	  aspects	  of	  concussions,	  brain	  contusions,	  and	  hemorrhages	  
seen	  in	  human	  TBI.	  Our	  pilot	  studies	  showed	  the	  feasibility	  of	  TBI-­‐induced	  chronic	  
epilepsy	  model	  in	  mice.	  Ganaxolone	  treatment	  had	  positive	  outcomes	  on	  motor	  
function	  and	  additional	  promising	  disease-­‐modifying	  or	  protective	  potential	  to	  reduce	  
epileptic	  seizures.	  This	  pilot	  study	  will	  be	  advanced	  further	  in	  a	  larger	  cohort	  to	  confirm	  
Ganaxolone’s	  ability	  to	  reduce	  or	  prevent	  PTE.
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BACKGROUND	  AND	  INTRODUCTION	  
1.1 Traumatic	  Brain	  Injury	  	  
Traumatic	  brain	  injury	  (TBI)	  is	  a	  major	  cause	  of	  mortality	  and	  morbidity,	  particularly	  at	  
the	  two	  ends	  of	  the	  age	  spectrum,	  with	  large	  direct	  and	  indirect	  costs	  to	  society.	  In	  the	  
United	  States	  (US)	  it	  has	  been	  estimated	  that	  more	  than	  1.7	  million	  individuals	  suffered	  
a	  TBI	  occurrence	  annually,	  whether	  through	  an	  isolated	  injury	  or	  in	  congruence	  with	  
another	  injury	  (Faul	  et	  al.,	  2010),	  and	  the	  annual	  burden	  of	  TBI	  has	  been	  estimated	  at	  
close	  to	  US	  $76.5	  billion	  (Finkelstein	  et	  al.,	  2006),	  though	  these	  numbers	  markedly	  
underestimate	  the	  incidences	  and	  costs.	  In	  US	  Center	  for	  Disease	  Control	  and	  
Prevention	  data	  (Faul	  et	  al.,	  2010)	  sports-­‐related	  injuries	  are	  not	  listed	  among	  the	  top	  
categories,	  but	  some	  have	  estimated	  the	  incidence	  of	  such	  head	  injuries	  at	  1.6–3.8	  
million	  per	  year	  (Langlois	  et	  al.,	  2006).	  Globally,	  the	  incidence	  of	  TBI	  is	  also	  increasing,	  
particularly	  in	  developing	  countries	  (Maas	  et	  al.,	  2008).	  In	  Europe,	  it	  is	  estimated	  to	  
cost	  health	  care	  an	  annually	  33	  billion	  euros	  for	  TBI,	  while	  among	  those	  suffering,	  a	  
large	  portion	  of	  the	  individuals	  will	  have	  physical	  disabilities	  that	  will	  lead	  to	  a	  burden	  
on	  the	  health	  care	  system.	  Perhaps	  more	  importantly	  though,	  is	  the	  functional	  
impairments	  that	  remain,	  adversely	  affecting	  the	  patient’s	  quality	  of	  life,	  and	  
exacerbating	  the	  burden	  of	  TBI	  on	  society	  (Weaver	  at	  al.	  2012,	  Dardiotis	  et	  al.	  2012;	  
2010).	  Moreover,	  TBI	  is	  also	  thought	  to	  lead	  to	  outcomes	  of	  physical	  inactivity	  such	  as	  
obesity,	  diabetes,	  and	  heart	  disease	  (Michael	  et	  al.	  2010;	  Gallek	  et	  al.,	  2011).	  
2	  
	  
TBI	  is	  a	  highly	  complex	  disorder	  that	  comprises	  varying	  degrees	  of	  contusion,	  DAI,	  
hemorrhage	  and	  hypoxia	  (Saatman	  et	  al.,	  2008,	  1983).	  TBI	  can	  be	  organized	  or	  
identified	  on	  the	  basis	  of	  the	  mechanism	  of	  injury	  (Graham	  et	  al.	  2009),	  and	  with	  these	  
classifications,	  we	  can	  group	  TBI	  injuries	  into	  characteristics	  of	  mechanical	  force	  
(acceleration,	  amplitude,	  duration,	  and	  velocity)	  determining	  if	  the	  injury	  is	  static	  or	  
dynamic.	  In	  terms	  of	  rating	  severity	  of	  TBI,	  the	  15-­‐point	  Glasgow	  Coma	  Scale	  (GCS)	  is	  
most	  commonly	  used.	  This	  rating	  scales	  measures	  three	  vital	  parameters:	  eye-­‐opening	  
response	  to	  stimuli,	  verbal,	  and	  motor	  (Marion,	  2000).	  To	  demonstrate	  this	  rating	  given	  
an	  example,	  we	  see	  in	  mild	  TBI	  (mTBI),	  a	  GCS	  score	  greater	  than	  or	  equal	  to	  thirteen,	  
while	  in	  moderate	  TBI	  we	  see	  a	  nine	  to	  twelve	  score,	  and	  in	  severe	  TBI,	  a	  score	  8	  or	  
less.	  Complicating	  the	  use	  of	  any	  scoring	  system,	  it	  should	  also	  not	  be	  assumed	  that	  the	  
same	  injury	  severity	  will	  have	  the	  same	  distribution	  of	  damage	  within	  the	  brain	  and	  the	  
type	  of	  damage	  whether	  that	  is	  gray	  or	  white	  matter	  (Saatman	  et	  al.	  2008).	  Regardless	  
of	  severity	  and	  pathological	  differences	  between	  severities	  though,	  collectively,	  these	  
effects	  induce	  biochemical	  and	  metabolic	  changes	  that	  lead	  to	  progressive	  tissue	  
damage	  and	  associated	  cell	  death	  (McIntosh,	  et	  al.,	  2008).	  The	  vital	  point	  here	  is	  that,	  
even	  though	  we	  can	  see	  the	  same	  injury	  severity	  amongst	  individuals,	  it	  should	  not	  be	  
assumed	  that	  they	  are	  both	  following	  the	  same	  pathological	  and	  clinical	  
endophenotypes.	  
TBI	  can	  result	  in	  the	  development	  of	  complex	  neurological	  deficits	  caused	  through	  
primary	  and	  secondary	  injury	  mechanisms.	  Primary	  injury	  events	  encompass	  the	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mechanical	  damage	  that	  occur	  at	  the	  time	  of	  trauma	  to	  neurons,	  axons,	  glia	  and	  blood	  
vessels	  as	  a	  result	  of	  shearing,	  tearing	  or	  stretching	  (Saatman	  et	  al.;	  Adams	  et	  al.,	  2008;	  
1983).	  In	  addition,	  secondary	  injury	  evolves	  over	  minutes	  to	  days	  and	  even	  months	  
after	  the	  initial	  traumatic	  insult	  and	  results	  from	  delayed	  biochemical,	  metabolic	  and	  
cellular	  changes	  that	  are	  initiated	  by	  the	  primary	  event.	  
This	  neurological	  disease	  is	  a	  significant	  and	  life-­‐altering	  health	  issue	  that	  affects	  many	  
service	  members	  and	  veterans	  during	  wars	  and	  following.	  It	  is	  often	  referred	  to	  the	  
signature	  wound	  of	  the	  Iraq	  and	  Afghanistan	  wars	  predominantly	  occurring	  through	  a	  
sudden	  traumatic	  or	  head	  related	  injury	  that	  disrupts	  the	  normal	  functions	  of	  the	  brain	  
(Tanielian,	  2008).	  The	  most	  common	  types	  of	  causations	  within	  the	  military	  include:	  
explosive	  devices,	  falls,	  and	  vehicle	  or	  motorcycle	  accidents.	  During	  the	  Iraq	  war,	  
several	  thousand	  military	  service	  members	  have	  sustained	  a	  TBI,	  69%	  of	  those	  as	  a	  
result	  of	  a	  blast	  (Warden,	  2006).	  There	  is	  an	  increased	  rate	  for	  sustaining	  a	  TBI	  injury	  in	  
active	  duty	  and	  reserve	  service	  members	  in	  comparison	  to	  civilians.	  These	  results	  are	  
due	  to	  multiple	  factors	  that	  include	  the	  specific	  demographics	  of	  the	  military,	  e.g.	  in	  
general,	  young	  men	  that	  are	  between	  the	  ages	  of	  18	  to	  24	  are	  at	  a	  greater	  risk	  of	  TBI.	  It	  
is	  routine	  within	  the	  military	  to	  see	  many	  training	  activities	  and	  operational	  
employments	  that	  can	  be	  physically	  demanding	  and	  potentially	  dangerous,	  even	  with	  
stringent	  safety	  measures	  in	  place.	  Military	  service	  members	  are	  constantly	  deployed	  
to	  high-­‐risk	  areas	  where	  they	  could	  potentially	  experience	  blast	  exposures	  from	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improvised	  explosive	  devices	  (IEDs),	  suicide	  bombers,	  mortar	  rounds,	  land	  mines	  and	  
rocket-­‐propelled	  grenades.	  	  
An	  analysis	  of	  data	  that	  was	  collected	  from	  March	  2004-­‐September	  2004	  from	  115	  
patients	  from	  the	  Navy-­‐Marine	  Corps	  that	  were	  identified	  with	  TBI	  showed	  that	  IEDs	  
were	  the	  most	  common	  mechanism	  of	  injury,	  and	  were	  responsible	  for	  52%	  of	  TBI	  
cases	  overall.	  In	  addition,	  the	  analysis	  showed	  that	  intracranial	  injuries,	  specifically	  
concussions,	  were	  the	  most	  common	  within	  diagnosis,	  and	  51%	  of	  the	  patient	  group	  
had	  only	  an	  intracranial	  injury	  with	  no	  accompanying	  open	  wound	  in	  the	  head	  or	  head	  
fractures.	  It	  was	  also	  found	  that	  115	  patients	  analyzed,	  roughly	  63%	  of	  the	  patients	  
were	  wearing	  helmets	  at	  the	  time	  of	  Injury	  (Clark	  et	  al.,	  2007).	  This	  augmented	  rate	  of	  
TBI	  and	  blast-­‐related	  concussion	  events	  that	  result	  from	  combat	  operations	  will	  lead	  to	  
a	  direct	  impact	  on	  the;	  health,	  safety,	  overall	  well-­‐being	  of	  individual	  service	  members,	  
affected	  families	  of	  service	  members,	  and	  fellow	  comrades.	  The	  high	  impacts	  of	  TBI	  are	  
shared	  within	  each	  branch	  of	  the	  service	  and	  throughout	  both	  the	  Department	  of	  
Defense	  (DOD	  and	  the	  Department	  of	  Veterans	  Affairs	  (VA)	  health	  care	  systems.	  
Specifically	  within	  the	  VA,	  TBI	  has	  become	  a	  large	  focus,	  leading	  to	  the	  
acknowledgement	  of	  the	  necessities	  for	  additional	  resources	  to	  provide	  health	  care	  and	  
vocational	  retraining	  for	  individuals	  that	  suffer	  from	  a	  TBI	  diagnosis,	  while	  they	  
transition	  from	  active	  duty.	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TBI	  is	  not	  limited	  to	  the	  realm	  of	  military	  combat	  situations	  but	  is	  also	  seen	  in	  sports.	  
The	  marked	  difference	  between	  combat-­‐related	  concussion	  and	  sports-­‐related	  
concussions	  is	  the	  mechanism	  of	  injury.	  Among	  the	  vast	  amount	  of	  people	  that	  suffer	  
from	  TBIs	  each	  year	  in	  the	  United	  States,	  approximately	  10%	  of	  those	  are	  due	  to	  sports	  
and	  recreational	  activities	  (Gilchrist	  et	  al.,	  2001;	  2009).	  	  In	  sport-­‐related	  concussion,	  the	  
most	  common	  causations	  of	  a	  TBI	  injury	  are	  through	  head-­‐to-­‐head	  impacts	  in	  helmeted	  
athletes.	  In	  the	  United	  States	  alone	  it	  is	  estimated	  that	  300,000	  sports-­‐related	  
concussions	  annually	  are	  due	  to	  high	  impact	  head-­‐to-­‐head	  collisions	  (Gessel	  et	  al,	  
2007).	  Sports	  are	  second	  only	  to	  motor	  vehicle	  accidents	  as	  one	  of	  the	  leading	  causes	  
of	  civilian	  concussions	  within	  individuals	  between	  the	  ages	  of	  15-­‐24.	  Concussions	  are	  
far	  more	  predominant	  in	  football	  (47.1%	  of	  the	  1,936	  concussions	  that	  occurred	  in	  high	  
school	  athletes	  during	  the	  2008-­‐2010	  school	  years)	  in	  comparison	  to	  any	  other	  sport,	  
with	  the	  next	  highest	  impact	  TBI	  sport	  among	  young	  men	  being	  hockey	  and	  lacrosse	  
(Marar	  et	  al.	  2010).	  As	  the	  numbers	  of	  participants	  in	  youth	  sports	  continue	  to	  grow,	  
the	  incidence	  of	  brain	  injuries	  proportionally	  rise	  as	  well	  (Gilchrist	  et	  al.,	  2009).	  In	  
congruence	  with	  these	  reports,	  we	  see	  an	  increased	  awareness	  for	  the	  potential	  short-­‐
and	  long-­‐term	  sequelae	  of	  sports	  players	  that	  suffer	  from	  brain	  related	  injuries,	  such	  as	  
the	  increased	  chance	  for	  re-­‐injury,	  cognitive	  deficiencies,	  early	  onset	  of	  Alzheimer’s,	  
chronic	  traumatic	  encephalopathy,	  and	  second	  impact	  syndrome	  (CDC	  1997;	  Cantu	  et	  
al.	  1995;	  Collins	  et	  al.	  1999;	  Lovell	  et	  al.,	  2003;	  Omalu	  et	  al.	  2010).	  The	  related	  clinical	  
signs	  and	  symptoms	  that	  follow	  an	  mTBI	  (mild	  Traumatic	  Brain	  Injury)	  in	  athletes	  can	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range	  from	  subtle	  mood	  changes	  to	  obvious	  loss	  of	  consciousness,	  the	  onset	  of	  which	  
can	  be	  immediate,	  or	  potentially	  several	  minutes	  after	  injury	  (Kelly	  Rosenberg,	  1997).	  	  
According	  to	  the	  American	  Academy	  of	  Neurology	  (AAN),	  the	  identifying	  signs	  of	  mTBI	  
are	  thought	  to	  be	  amnesia,	  behavior	  or	  personality	  changes,	  confabulation,	  delayed	  
verbal	  and	  motor	  responses,	  disequilibrium,	  disorientation,	  emotional	  liability,	  loss	  of	  
consciousness,	  slurred/incoherent	  speech,	  or	  a	  vacant	  stare.	  Symptoms	  of	  mTBI	  may	  
include	  blurry/double	  vision,	  confusion,	  dizziness,	  excessive	  drowsiness,	  sleep	  
difficulties,	  hazy	  feelings,	  foggy	  or	  groggy,	  headache,	  inability	  to	  focus	  or	  concentrate	  
nausea,	  vomiting,	  and	  photo-­‐	  or	  phonophobia	  (AAN	  1997).	  It	  is	  vitally	  important	  that	  
clinicians	  consider	  their	  evaluations	  of	  athletes	  as	  a	  unique	  population	  subset,	  simply	  
because	  the	  sporting	  world	  has	  a	  culture	  and	  mental	  perspective	  that	  predicates	  the	  
pushing	  of	  athletes	  beyond	  their	  perceived	  physical	  and	  mental	  abilities	  on	  and	  off	  the	  
field,	  where	  even	  the	  slightest	  injury	  can	  be	  compounded	  if	  left	  untreated	  or	  
undiagnosed.	  	  In	  response	  to	  increased	  TBI	  injuries	  amongst	  sports	  players,	  the	  Federal	  
and	  State	  governments,	  in	  congruence	  with	  multiple	  sports	  governing	  officials	  and	  
companies	  have	  implemented	  rule	  and	  policy	  changes	  that	  are	  specifically	  designed	  to	  
increase	  the	  protection	  of	  athletes	  and	  to	  standardize	  medical	  care.	  	  
TBI	  presents	  a	  significant	  public	  challenge	  in	  today’s	  society,	  and	  approximately	  1.7	  
million	  civilians	  in	  the	  U.S.	  each	  year	  suffer	  from	  some	  form	  of	  TBI	  that	  will	  at	  least	  
require	  a	  hospital	  visit	  (Faul	  et	  al.,	  2010).	  The	  fraction	  of	  severe	  TBI	  cases	  within	  the	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general	  population-­‐which	  is	  around	  3%	  of	  total	  annual	  cases-­‐	  is	  deemed	  to	  require	  the	  
most	  intensive	  medical	  care	  and	  is	  more	  often	  than	  not	  complicated	  by	  additional	  
injuries	  to	  other	  body	  regions.	  Moderate	  brain	  injury	  within	  the	  general	  population	  
represents	  roughly	  22%	  of	  the	  annual	  incidence	  and	  commonly	  renders	  victims	  with	  
persistent	  deficits	  that	  will	  follow	  them	  the	  rest	  of	  their	  life.	  Mild	  TBI,	  though	  
egregiously	  under-­‐diagnosed	  due	  to	  the	  lack	  of	  response	  on	  the	  victim	  or	  surrounding	  
affected	  friends	  or	  family,	  has	  the	  highest	  incidence	  rate	  in	  the	  general	  population-­‐75%	  
of	  total	  TBI	  injuries	  accrued-­‐	  and	  may	  potentially	  be	  higher	  than	  reported	  in	  
epidemiological	  studies,	  owing	  to	  the	  prior	  mentioned	  underreported	  cases	  in	  young	  
populations	  (Laker,	  2011).	  In	  total,	  the	  socioeconomic	  toll	  is	  daunting,	  and	  TBI	  remains	  
the	  number	  one	  prevalent	  cause	  of	  death	  in	  adults	  aged	  less	  than	  45	  years	  old	  and	  is	  
considered	  to	  be	  the	  highest	  cause	  of	  long-­‐term	  disability	  (CDC,	  2013).	  Additionally	  as	  
the	  population	  ages,	  we	  are	  seeing	  an	  increased	  incidence	  in	  the	  elderly	  population,	  
where	  TBI	  is	  now	  only	  second	  to	  cancer	  as	  a	  causation	  of	  death	  in	  individuals	  over	  the	  
age	  of	  65	  (Coronado	  et	  al.,	  2007).	  Thus	  with	  the	  growing	  awareness	  of	  TBI	  in	  civilian,	  
sports	  and	  military	  populations,	  it	  is	  no	  longer	  considered	  a	  silent	  epidemic.	  	  
Neuroprotection	  approaches	  for	  both	  acute	  and	  chronic	  neurodegenerative	  disorders	  
have	  historically	  been	  dominated	  by	  a	  neuronocentric	  view	  in	  which	  modification	  of	  
neuronal-­‐based	  injury	  mechanisms	  is	  the	  primary	  or	  even	  exclusive	  focus	  of	  the	  
neuroprotective	  strategy.	  However,	  increasing	  evidence	  in	  the	  literature	  underscores	  
the	  importance	  of	  viewing	  injury	  more	  broadly	  to	  include	  endothelial	  cells,	  astroglia,	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microglia,	  oligodendroglia	  and	  precursor	  cells.	  More	  recent	  neuroprotection	  
approaches	  have	  recognized	  this	  complex	  structure	  and	  interplay,	  emphasizing	  
therapeutic	  strategies	  that	  promote	  the	  recovery	  and	  optimal	  functioning	  of	  non-­‐
neuronal	  cells	  in	  addition	  to	  inhibiting	  neuronal	  cell	  death	  pathways	  (Stoica	  et	  al.,	  2009;	  
Nimmo,	  2009).	  	  
1.2 Epidemiology	  
TBI	  injuries	  can	  be	  classified	  as	  one	  of	  the	  singular	  causes	  of	  death	  seen	  in	  patients	  
under	  the	  age	  of	  25	  and	  considered	  to	  be	  responsible	  for	  one	  third	  of	  all	  deaths	  
involving	  a	  trauma	  experience	  (Kasmaei	  et	  al.,	  2015).	  Therefore,	  the	  importance	  of	  
collecting	  epidemiologic	  patterns	  and	  education	  between	  different	  populations	  is	  vitally	  
needed	  for	  gaining	  knowledge	  into	  the	  epidemiology	  of	  this	  high-­‐impact	  disease.	  	  
According	  to	  the	  CDC,	  an	  estimated	  1.7	  million	  documented	  cases	  of	  TBI	  are	  reported	  
annually,	  with	  an	  unreported	  analysis	  suggesting	  upwards	  of	  3.8	  million	  (CDC,	  2013).	  
Direct	  and	  indirect	  cost	  associated	  with	  medical	  attention	  for	  TBI	  patients	  before	  and	  
after	  injury	  totaled	  in	  the	  United	  States	  in	  the	  year	  2000	  roughly	  $76.5	  billion	  
(Finkelstein	  et	  al.	  2006,	  Coronado,	  2007).	  	  From	  2001-­‐2009,	  US	  physicians	  annually	  
treated	  around	  170,000	  cases	  of	  mTBI	  in	  adolescents	  (0-­‐19yo)	  (Gilchrist	  et	  al.,	  2001-­‐
2009).	  During	  the	  same	  10	  year	  period,	  emergency	  departments	  visits	  for	  both	  
recreational-­‐	  and	  sports-­‐related	  injuries	  (mTBIs)	  among	  children	  and	  young	  adults	  
increased	  by	  a	  60%	  annual	  rate	  (Gilchrist	  et	  al.	  2001-­‐2009)	  from	  153,375,	  in	  2001	  to	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248,418	  in	  2009	  (Morbidity	  and	  Mortality	  Weekly	  Report,	  2011).	  	  From	  1997-­‐2007	  
emergency	  department	  visits	  involving	  mTBI	  injuries	  from	  organized	  sports	  doubled	  in	  
children	  (8-­‐13yo),	  and	  tripled	  in	  young	  adults	  (14-­‐19yo)	  (Mitka,	  2010).	  A	  thorough	  
analysis	  of	  these	  results	  show	  that	  71%	  of	  all	  sports-­‐	  and	  recreation-­‐related	  TBI	  
emergency	  department	  visits	  were	  in	  males	  between	  the	  ages	  of	  ten	  to	  nineteen	  
(Gilchrist,	  et	  al.,	  2001-­‐2009).	  Furthermore,	  the	  activities	  that	  were	  predominantly	  
linked	  with	  TBI-­‐related	  emergency	  department	  visits	  were	  football	  and	  bicycling,	  and	  
closely	  followed	  by	  soccer,	  basketball,	  and	  playground	  activities	  (Gilchrist	  et	  al.,	  2001-­‐	  
2009).	  	  
In	  a	  recent	  cross	  sectional	  study,	  1000	  patients	  affected	  through	  some	  sort	  of	  TBI	  injury	  
were	  profiled	  using	  a	  simple	  random	  sampling	  technique.	  Within	  the	  study,	  the	  
variables	  that	  were	  examined	  included:	  outcome	  of	  patient,	  admission	  to	  ICU	  care,	  
computed	  tomography	  scan	  results,	  surgery	  care,	  level	  of	  consciousness,	  accompanying	  
injuries,	  hospitalization	  stay,	  demographics,	  season,	  and	  mechanism	  of	  injury.	  The	  
results	  showed	  that	  within	  the	  1000	  patients	  that	  were	  affected	  by	  TBI,	  81.8%	  were	  
males	  with	  a	  mean	  age	  between	  38.5±21.7	  years	  old.	  In	  spring,	  the	  hospital	  referral	  
rate	  of	  individuals	  within	  the	  study	  was	  31.4%;	  more	  than	  any	  other	  season	  (p<0.01).	  
The	  researchers	  used	  the	  Glasglow	  Coma	  Scale	  (lower	  scores	  correlated	  with	  
deficiencies	  of	  normal	  functions),	  which	  measures	  Eye	  Opening	  (1-­‐4),	  Verbal	  Response	  
(1-­‐5),	  and	  Motor	  Response	  (1-­‐6)	  to	  measure	  consciousness	  within	  their	  test	  subjects.	  
Their	  results	  showed	  45.9%	  had	  some	  level	  of	  a	  “coma”	  measuring	  less	  than	  nine	  on	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that	  scale.	  According	  to	  CT	  scans,	  45.9%	  had	  subdural	  bleeding,	  23.7%	  had	  epidural	  
bleeding,	  and	  23.3%	  patients	  suffered	  mortalities.	  These	  results	  suggest	  an	  increased	  
frequency	  of	  TBI	  in	  male	  patients	  20-­‐60	  years	  old	  (Kasmaei,	  2015).	  
1.3 Pathophysiological	  Mechanisms	  	  
An	  injury	  considered	  to	  be	  a	  trademark	  of	  TBI	  is	  a	  DAI	  (Diffuse	  Axonal	  Injury)	  and	  
commonly	  is	  initiated	  during	  the	  early	  phases	  of	  neuronal	  and	  parenchymal	  damage,	  as	  
a	  direct	  result	  of	  varying	  traumatic	  external	  forces.	  DAI	  is	  a	  consequence	  of	  various	  
rotational	  forces,	  and	  is	  vital	  to	  differentiate	  between	  cortical	  concussions	  and	  other	  
differing	  hemorrhages	  that	  may	  be	  caused	  by	  linear	  acceleration/deceleration	  injuries	  
(Goodman,	  1994).	  Unfortunately,	  the	  primary	  injury	  may	  not	  always	  be	  treatable	  and	  
thus	  can	  lead	  to	  fatal	  conditions.	  At	  a	  macroscopic	  level,	  damages	  may	  include	  shearing	  
of	  white	  matter	  tracts,	  focal	  contusions,	  hematomas,	  and	  diffuse	  edema.	  At	  the	  cellular	  
level,	  it	  is	  common	  to	  see	  premature	  sequelae	  of	  neurotrauma,	  such	  as:	  stearic	  
conformational	  changes	  in	  proteins,	  leaky	  ion	  channels,	  and	  microporation	  of	  
membranes.	  Another	  common	  result	  that	  is	  seen	  during	  a	  neurotraumatic	  event	  is	  the	  
appearance	  of	  micro-­‐hemorrhages,	  due	  to	  the	  tearing	  of	  blood	  vessels	  (Maas	  et	  al.,	  
2008).	  It	  is	  very	  clear	  that	  the	  most	  critical	  factor	  for	  diminishing	  damage	  resulting	  from	  
a	  primary	  injury	  is	  through	  preventative	  measures.	  	  
	  A	  secondary	  delayed-­‐phase	  may	  occur	  within	  hours,	  to	  days	  to	  weeks,	  and	  has	  been	  
observed	  in	  TBI	  models	  to	  include:	  inflammatory	  cascade	  activation,	  edema,	  ischemia,	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free	  radical	  effects,	  excitatory	  amino	  acids,	  ion	  release,	  and	  programmed	  cell	  death	  
(Chestnut,	  Marshall,	  1993).	  More	  often	  than	  not,	  one	  will	  see	  a	  disruption	  of	  axonal	  
neurofilament	  organization	  occurring	  that	  results	  in	  an	  impairment	  of	  axonal	  transport	  
that	  then	  lead	  to	  axonal	  swelling,	  Wallerian	  degeneration,	  and	  transection	  (Povlishock	  
and	  Katz,	  2005).	  Additional	  secondary	  injuries	  may	  be	  due	  to	  the	  release	  of	  excitatory	  
neurotransmitters	  such	  as	  acetylcholine,	  glutamate	  and	  aspartate,	  and	  the	  generation	  
of	  free	  radicals.	  	  
The	  pathophysiology	  of	  TBI	  that	  is	  involved	  in	  both	  focal	  and	  diffuse	  damage	  is	  
multifaceted	  and	  heterogeneous,	  something	  that	  must	  be	  accounted	  for	  when	  
designing	  neuroprotective	  treatments.	  Current	  and	  future	  studies	  should	  focus	  on	  
elucidating	  why	  many	  neuroprotective	  therapies,	  to	  date	  have	  yet	  to	  yield	  results	  that	  
improve	  the	  clinical	  outcome	  in	  this	  neurodegenerative	  disease.	  Two	  major	  
neurodegenerative	  diseases	  that	  are	  commonly	  linked	  with	  the	  pathology	  of	  a	  
traumatic	  brain	  event	  are	  Alzheimer’s	  disease	  and	  Parkinson’s	  disease.	  	  	  
1.4 TBI	  and	  Epileptogenesis	  
Epilepsy	  is	  a	  multifaceted	  diagnosis	  that	  is	  comparative	  to	  the	  complexity	  of	  the	  
terminology.	  The	  ILAE	  (International	  League	  Against	  Epilepsy)	  definition	  defines	  
epilepsy	  as	  a	  history	  of	  at	  least	  one	  ictal	  event,	  with	  an	  enduring	  alteration	  in	  the	  brain	  
that	  elevates	  the	  possibilities	  of	  future	  seizures	  as	  well	  as	  associated	  neurobiological,	  
cognitive,	  psychological,	  and	  social	  disturbances	  (Fisher	  et	  al.,	  2005).	  	  As	  illustrated	  in	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Figure	  1,	  depending	  on	  the	  time	  of	  delay	  from	  TBI	  to	  the	  occurrence	  of	  the	  first	  
seizures,	  post-­‐TBI	  seizures	  are	  categorized	  into	  immediate	  (<24	  h),	  early	  (1-­‐7	  days),	  or	  
late	  seizures	  (>	  1	  week	  after	  TBI)	  (Annegers	  et	  al.,	  1998).	  Therefore	  the	  association	  of	  
TBI	  and	  a	  single	  unprovoked	  late	  seizure	  can	  be	  characterized	  as	  post-­‐traumatic	  
epilepsy	  (PTE)	  diagnosis.	  	  
PTE	  is	  responsible	  for	  10-­‐20%	  of	  symptomatic	  epilepsy	  in	  the	  general	  population	  and	  
5%	  of	  all	  epilepsy	  (Herman,	  2002).	  Within	  civilian	  and	  military	  populations	  
epidemiologic	  studies,	  the	  majority	  of	  which	  that	  were	  conducted	  before	  the	  relevant	  
imaging	  era,	  the	  risk	  factors	  for	  PTE	  are	  inclusive	  to	  penetrating	  injuries,	  old	  age,	  injury	  
severity	  (GSC<10),	  intracranial	  hemorrhage,	  bi-­‐parietal	  or	  multiple	  contusions,	  frontal	  
or	  temporal	  locations	  of	  lesion,	  >5	  mm	  brain	  midline	  shift,	  duration	  of	  coma	  >24	  h,	  loss	  
of	  consciousness	  >24	  h,	  prolonged	  length	  of	  post-­‐traumatic	  amnesia,	  multiple	  
intracranial	  procedures,	  and	  the	  occurrence	  of	  early	  post-­‐traumatic	  seizures	  (Herman,	  
2000).	  In	  terms	  of	  methodology,	  the	  majority	  of	  the	  risk	  factors	  that	  have	  been	  
identified	  are	  directly	  or	  indirectly	  comparative	  to	  the	  severity	  of	  brain	  injury,	  





Figure	  1.	  Schematic	  illustration	  adapted	  from	  Hunt	  et	  al.	  (2013)	  of	  TBI-­‐Induced	  




The	  progression	  of	  an	  acquired	  epileptic	  disorder	  suggests	  an	  abnormal	  neuronal	  
reorganization	  that	  happens	  over	  an	  extended	  period	  of	  time	  following	  a	  specific	  
cerebral	  insult	  (Engel,	  1989).	  Such	  morbidities	  include	  neurodegeneration,	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neurogenesis,	  axonal	  sprouting,	  axonal	  injury,	  glial	  cell	  activation	  invasion	  of	  peripheral	  
inflammatory	  cells,	  vascular	  damage	  and	  angiogenesis,	  alterations	  to	  the	  extracellular	  
matrix,	  and	  changes	  in	  the	  molecular	  structure	  of	  cellular	  facets	  such	  as	  receptor-­‐gated	  
ion	  channels,	  and	  ligands.	  The	  majority	  of	  these	  alterations	  are	  normally	  discovered	  at	  
the	  time	  when	  seizure	  threshold	  is	  diminished	  and	  devoid	  of	  spontaneous	  seizure	  
occurrences.	  They	  will	  then	  proceed	  to	  develop	  beyond	  the	  time	  of	  the	  initial	  
unprovoked	  seizure	  and	  can	  even	  be	  implicated	  long	  after	  epilepsy	  diagnosis	  (Pitkanen	  
and	  Sutula,	  2002).	  From	  the	  viewpoint	  of	  a	  neurobiologist,	  the	  starting	  point	  of	  
epileptogenic	  network	  reorganization	  can	  be	  defined	  as	  the	  direct	  moment	  of	  insult	  
such	  as	  a	  TBI.	  Conversely,	  it	  is	  difficult	  to	  define	  the	  endpoint	  of	  epileptogenesis,	  
especially	  relative	  to	  the	  number	  of	  seizures.	  	  
In	  humans,	  the	  detailed	  neurobiology	  of	  epileptogenesis	  following	  various	  brain	  insults	  
is	  poorly	  known.	  The	  data	  that	  is	  available	  would	  suggest	  that	  the	  majority	  of	  patients	  
acquire	  epilepsy	  within	  2	  years	  after	  SE,	  TBI,	  or	  stroke,	  which	  would	  implicate	  some	  
connections	  between	  etiologies	  (Bladin	  et	  al.,	  2000).	  Roughly	  10-­‐20%	  of	  acquired	  
epilepsy	  is	  caused	  by	  TBI	  with	  a	  30-­‐year	  overall	  incidence	  of	  epilepsy	  being	  2.1%	  for	  
mild,	  4.2%	  for	  moderate,	  and	  16.7%	  for	  severe	  injuries.	  TBI	  patients	  that	  suffer	  from	  a	  
penetrating	  head	  injury	  such	  as	  a	  bullet	  wound,	  up	  to	  53%	  develop	  epilepsy.	  	  In	  roughly	  
8-­‐10%	  of	  cases,	  epilepsy	  develops	  within	  2	  years,	  though	  the	  elevated	  risk	  can	  reach	  up	  
to	  10	  years	  post-­‐TBI	  (Haltiner	  et	  al.,	  1997).	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1.5 Animal	  Model	  
In	  accordance	  with	  the	  heterogeneous	  nature	  of	  clinical	  circumstances	  in	  TBI,	  a	  number	  
of	  animal	  model	  have	  evolved.	  Larger	  mammals	  are	  more	  interpretable	  to	  human	  
physiology	  for	  research	  purposes,	  but	  rodents	  are	  mostly	  used	  in	  TBI	  research	  due	  to	  
their	  low	  costs,	  small	  size	  and	  the	  ability	  to	  standardize	  resulting	  outcomes.	  More	  
recent	  models	  of	  TBI	  have	  been	  geared	  toward	  targeting	  and	  expanding	  our	  knowledge	  
of	  the	  detrimental,	  and	  complex	  molecular	  cascades	  that	  are	  due	  to	  the	  results	  of	  
traumatic	  head	  injuries.	  Among	  the	  current	  models,	  four	  are	  commonly	  used	  in	  
research:	  fluid	  percussion	  injury	  (FPI)	  (Dixon	  et	  al.,	  1987),	  cortical	  impact	  injury	  (CCI)	  
(Lightwall,	  1988),	  weight	  drop-­‐impact	  acceleration	  injury	  (Marmarou	  et	  al.,	  1994),	  and	  
blast	  injury	  (Cernak	  et	  al.,	  1996).	  Within	  the	  study,	  we	  utilized	  the	  CCI	  model.	  	  
In	  the	  CCI	  model,	  a	  pneumatic	  or	  electromagnetic	  impact	  device	  drives	  a	  rigid	  impactor	  
into	  the	  exposed	  intact	  dura,	  and	  replicates	  the	  cortical	  tissue	  loss,	  acute	  subdural	  
hematoma,	  axonal	  injury,	  concussion,	  blood-­‐brain	  barrier	  (BBB)	  dysfunction	  and	  also	  
coma	  (Dixon	  1991;	  Lighthall	  1988;	  Smith	  et	  al.,	  1995;	  Morales	  2005;	  Lighthall	  et	  al.,	  
1990).	  This	  model	  has	  been	  used	  on	  ferret,	  rats,	  mice,	  swine,	  and	  monkeys,	  and	  is	  
delivered	  to	  the	  intact	  dura	  in	  the	  form	  of	  a	  unilateral	  craniotomy.	  This	  technique	  is	  
most	  often	  applied	  between	  the	  bregma	  and	  lambda	  and	  results	  in	  a	  deformation	  of	  
the	  underlying	  cortex	  (Dixon	  et	  al.,	  1991).	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One	  of	  the	  positive	  attributes	  associated	  with	  the	  model	  in	  comparison	  with	  other	  TBI	  
models	  is	  the	  enhanced	  control	  of	  mechanical	  factors,	  time,	  velocity	  and	  depth	  of	  
impact.	  All	  these	  factors	  make	  it	  a	  more	  useful	  model	  than	  the	  FPI	  model	  for	  
biomechanical	  studies	  of	  TBI	  (Mao	  et	  al.	  2010;	  Hall	  et	  al.,	  2005).	  An	  additional	  positive	  
attribute	  of	  CCI,	  in	  comparison	  with	  other	  models	  that	  are	  gravity-­‐driven	  devices,	  is	  the	  
relative	  increased	  safety	  allowing	  for	  increasing	  cortical	  deformation	  and	  impact	  
velocity,	  providing	  data	  in	  severe,	  but	  survivable	  injuries	  (Goodman	  et	  al.,	  1994;	  
Saatman	  et	  al.,	  2006).	  With	  the	  elevation	  of	  cortical	  deformation	  and	  impact	  velocity,	  
we	  see	  an	  increase	  in	  histopathological	  severity	  of	  CCI.	  This	  allows	  for	  the	  adjustment	  
of	  the	  severity	  injury	  deemed	  proportionate	  for	  specific	  experimental	  requirements.	  
Within	  this	  model,	  functional	  deficit	  such	  as	  cognitive	  impairments	  are	  measured	  using	  
the	  Morris	  water	  maze	  test,	  and	  are	  strongly	  associated	  with	  both	  the	  depth	  of	  
deformation	  and	  the	  velocity	  of	  the	  impact	  in	  mice	  and	  rat	  models	  (Fox	  et	  al.,	  1998;	  
Marklunc	  and	  Hillered,	  2011).	  The	  model	  shows	  a	  deficit	  in	  emotional	  behavior	  that	  
was	  also	  quantified	  in	  the	  forced	  swim	  test,	  elevated-­‐plus	  maze,	  and	  pre-­‐pulse	  
inhibition	  of	  acoustic	  startle	  in	  mice	  (Kochanek	  et	  al.,	  2002).	  In	  relation	  to	  injury	  
severity,	  we	  see	  a	  strong	  association	  of	  elevated	  cognitive	  deficiencies	  that	  suggest	  the	  
threshold	  for	  emotional	  changes	  post	  experimental	  TBI	  is	  low	  (Washington	  et	  al.	  2012).	  
Despite	  its	  cost	  and	  complexity,	  the	  swine	  CCI	  model	  has	  the	  ability	  to	  replicate	  injury	  
that	  shares	  common	  pathologic	  features	  similar	  to	  human	  TBI.	  This	  large	  animal	  model	  
presents	  us	  with	  the	  opportunity	  to	  gather	  physiological	  data	  post	  brain	  injury,	  in	  a	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scenario	  that	  would	  mimic	  the	  intensive	  care	  unit	  and	  may	  further	  facilitate	  translation	  
of	  animal	  data	  into	  clinical	  practice	  (Alessandri	  et	  al.,	  2003).	  
1.6	  Treatment	  Strategies	  
1.6.1	  Antiepileptic	  Drugs	  	  
Seizures	  are	  a	  common	  post-­‐TBI	  symptom	  that	  affects	  roughly	  50%	  of	  patients	  up	  to	  15	  
years	  following	  a	  penetrating	  injury.	  Post-­‐traumatic	  injuries	  can	  be	  identified	  within	  
weeks	  or	  as	  late	  as	  years,	  with	  incidence	  rates	  of	  4%-­‐25%	  and	  9%-­‐42%,	  respectively,	  in	  
untreated	  patients	  (Klein	  et	  al.,	  2008).	  According	  to	  the	  Brain	  Trauma	  Foundation	  (BTF)	  
management	  guidelines,	  level	  I	  recommendations	  for	  anti-­‐seizure	  prophylaxis	  do	  not	  
exist,	  but	  instead	  level	  II	  recommendations	  suggest	  using	  anticonvulsants	  such	  as	  
phenytoin	  and	  valproate	  to	  prevent	  early	  seizures.	  These	  anticonvulsants	  do	  not	  
prevent	  late	  seizures.	  Additional	  anticonvulsants,	  such	  as	  phenobarbital	  and	  
carbamazepine	  are	  generally	  not	  used	  due	  to	  adverse	  effects	  and	  pharmacodynamics	  
profiles.	  Besides	  acute	  therapy,	  there	  seems	  to	  be	  a	  relative	  paucity	  in	  pharmacological	  
options	  for	  epilepsy	  post-­‐TBI.	  Though,	  recent	  preliminary	  trials	  have	  revealed	  some	  
promising	  agents	  that	  are	  listed	  below.	  	  
1.6.2	  Anti-­‐Inflammatory	  Agents	  	  
Damage	  that	  is	  acquired	  through	  a	  primary	  injury	  is	  almost	  impossible	  to	  treat,	  which	  is	  
why	  researchers	  and	  clinicians	  focus	  on	  secondary	  cell	  death	  when	  developing	  
treatments	  for	  TBI.	  The	  delayed	  onset	  of	  damage	  that	  is	  caused	  by	  secondary	  events	  
allows	  for	  a	  window	  of	  opportunity	  to	  treat	  TBI	  victims.	  This	  makes	  it	  extremely	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convenient	  to	  target	  neuroinflammation	  for	  TBI	  therapy.	  It	  should	  be	  taken	  into	  
consideration	  when	  developing	  treatments	  for	  neuroinflammation	  in	  TBI;	  inflammation	  
can	  be	  both	  beneficial	  and	  detrimental.	  Prior	  studies	  have	  indicated	  that	  high	  
concentration	  of	  anti-­‐inflammatory	  agents	  can	  actually	  lead	  to	  worse	  outcomes.	  	  
Multiple	  stand-­‐alone	  drugs	  have	  been	  implicated	  and	  used	  for	  the	  targeting	  and	  
treatment	  of	  inflammation	  in	  TBI.	  Minocycline,	  a	  tetracycline	  derivative	  that	  holds	  anti-­‐
inflammatory	  properties,	  is	  one	  of	  these	  potential	  treatment	  drugs	  for	  TBI	  (Lampl	  et	  al.,	  
2007;	  Ma	  et	  al.,	  2007).	  In	  studies	  using	  animal	  models,	  minocycline	  showed	  
improvement	  in	  both	  tissue	  damage	  and	  inflammation	  that	  lead	  to	  improved	  
outcomes.	  The	  drug	  decreases	  the	  secretion	  of	  proinflammatory	  cytokines	  and	  
chemokines,	  that	  when	  taken	  together	  with	  other	  mediators	  in	  inflammation,	  can	  
reduce	  nitric	  oxide	  through	  direct	  scavenging	  and	  inhibition	  of	  over-­‐activation	  and	  
proliferation	  of	  microglia	  cells	  (Jordan	  et	  al.,	  2007;	  Sanchez	  Mejia	  et	  al.,	  2001).	  The	  
targeting	  of	  microglial	  cells	  is	  vital	  to	  linking	  together	  the	  reduction	  of	  cytokines	  IL-­‐
1beta,	  IL-­‐6	  and	  MMp-­‐9,	  all	  of	  which	  mediate	  the	  proinflammatory	  response	  (Jordan	  et	  
al.,	  2007;	  Sanchez	  Mejia	  et	  al.,	  2001).	  	  
An	  additional	  stand-­‐alone	  drug	  that	  is	  being	  investigated	  is	  melatonin.	  Melatonin	  is	  a	  
hormone	  from	  the	  pineal	  gland,	  and	  has	  shown	  to	  possess	  some	  neuroprotective	  
properties	  (Campolo	  et	  al.,	  2013).	  As	  a	  lipophilic	  enzyme,	  it	  can	  easily	  access	  cell	  
membranes	  to	  carry	  out	  its	  function.	  Its	  anti-­‐inflammatory	  properties	  are	  thought	  to	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inhibit	  microglial	  activation	  and	  lower	  secretion	  of	  proinflammation	  cytokines	  that	  
include	  IL-­‐1beta	  and	  TNF-­‐alpha	  (Wang	  et	  al.,	  2013;	  Ding	  et	  al.,	  2014)	  which	  are	  directly	  
connected	  with	  increased	  inflammatory	  response.	  Successful	  trials	  have	  showed	  
decreased	  brain	  edema	  and	  reduced	  cortical	  neural	  degeneration,	  suggesting	  
improvements	  in	  cognitive	  deficits	  (Ding	  et	  al.,	  2014).	  	  
G-­‐CSF,	  a	  drug	  that	  has	  been	  approved	  by	  the	  US	  Food	  and	  Drug	  Administration	  for	  TBI	  
treatment,	  is	  a	  cytokine	  that	  acts	  through	  receptor-­‐mediated	  transport	  by	  recruiting	  
endogenous	  stem	  cells,	  found	  in	  bone	  marrow	  into	  the	  peripheral	  blood.	  This	  allows	  for	  
the	  stem	  cells	  to	  act	  as	  promoters	  for	  neuroprotection	  at	  the	  injury	  site	  (Acosta	  et	  al.,	  
2014).	  Experimental	  date	  has	  suggested	  that	  G-­‐CSF	  can	  cross	  the	  BBB	  and	  bind	  to	  the	  
G-­‐CSF	  receptor	  on	  neurons	  and	  microglia	  leading	  to:	  inflammatory	  cytokine	  down-­‐
regulation,	  angiogenesis	  promotion,	  and	  antiapoptotic	  triggered	  pathways	  (Acosta	  et	  
al.,	  2014).	  	  Stem	  cells	  mobilized	  from	  bone	  marrow	  can	  additionally	  interact	  indirectly	  
in	  the	  periphery	  through	  synthesizing	  and	  releasing	  trophic	  growth	  factors,	  
chemokines,	  and	  cytokines	  that	  contribute	  to	  the	  protection	  of	  damage	  tissue	  and	  lead	  
to	  improved	  brain	  repair	  (Acosta	  et	  al.,	  2014).	  	  
TBI	  is	  highly	  implicated	  in	  long-­‐term	  neurodegenerative	  diseases	  and	  is	  linked	  to	  the	  
risk	  factors	  in	  the	  development	  of	  Alzheimer’s	  disease	  (AD).	  A	  hallmark	  sign	  of	  AD	  or	  
similar	  neurodegenerative	  diseases	  are	  the	  presence	  of	  Beta	  amyloid	  (AB)	  peptide	  
deposits.	  These	  deposits	  increase	  following	  a	  TBI	  in	  both	  animal	  models	  and	  patients	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who	  have	  suffered	  head	  traumas	  (Ekici	  et	  al.,	  2014).	  Lithium	  has	  the	  ability	  to	  inhibit	  
GSK-­‐3	  activity	  through	  alleviating	  beta	  amyloid	  deposits	  (Yu	  et	  al.,	  2012).	  A	  study	  in	  
mice	  treated	  with	  lithium	  following	  a	  TBI	  resulted	  in	  significant	  reductions	  of	  beta	  
amyloid	  deposits	  through	  B-­‐secretase	  inhibition.	  Lithium	  is	  thought	  to	  block	  Beta-­‐
secretase	  1	  (BACE1)	  expression,	  upregulated	  in	  humans	  and	  rats	  following	  head	  
damage,	  resulting	  in	  a	  reduction	  of	  AB	  load.	  Partially,	  this	  leads	  to	  the	  contributory	  
effects	  of	  improved	  spatial	  learning/memory	  and	  improved	  hippocampal	  preservation,	  
determined	  by	  enhanced	  neurobehavioral	  testing	  with	  TBI	  and	  sham	  groups	  (Blasko	  et	  
al.,	  2004;	  Loane	  et	  al.,	  2009;	  Uryu	  et	  al.,	  2007;	  Yu	  et	  al.,	  2012).	  
HDAC	  Inhibitors.	  The	  regulation	  of	  histone	  deacetylase	  (HDAC)	  inhibition	  is	  also	  thought	  
to	  be	  neuroprotective	  in	  nature.	  Its	  ability	  to	  restore	  histone	  acetylation	  levels	  and	  
correct	  transcriptional	  deficits	  involving	  multiple	  models	  of	  brain	  disorders	  has	  been	  a	  
main	  focus	  in	  TBI	  rodent	  models	  (Chuang	  et	  al.,	  2009;	  Dash	  et	  al.,	  2009;	  Shein	  et	  al.,	  
2009;	  Zhang	  et	  al.,	  2008).	  A	  recent	  study	  in	  2013	  by	  Fengshan	  and	  colleagues	  
demonstrated	  the	  effects	  of	  pooled	  sub-­‐therapeutic	  valproate	  (VPA)-­‐an	  additional	  
mood	  stabilizing	  drug-­‐	  and	  lithium	  in	  a	  mouse	  model	  of	  TBI.	  Both	  lithium	  and	  VPA	  
maintained	  the	  BBB	  through	  the	  inhibition	  of	  HDAC	  and	  TBI-­‐induced	  MMP-­‐9	  
overexpression	  (Yu	  et	  al.,	  2013;	  Wang	  et	  al.,	  2012;	  Chiu	  et	  al.,	  2013).	  Combined	  sub-­‐
effective	  doses	  of	  lithium	  and	  VPA	  resulted	  in	  a	  significant	  decline	  of	  lesion	  volume	  
while	  simultaneously	  preserving	  the	  BBB	  integrity	  in	  three-­‐day	  post-­‐TBI.	  This	  was	  not	  
seen	  in	  treatment	  groups	  when	  lithium	  and	  VPA	  were	  used	  alone.	  Lithium	  alone	  did	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show	  enhancements	  in	  fine	  motor	  neurobehavior	  at	  days	  14	  and	  21,	  but	  combined	  
treatments	  had	  more	  profound	  effects	  with	  significantly	  less	  Fluoro-­‐Jade	  B	  (FJB)-­‐	  a	  dye	  
utilized	  for	  the	  labeling	  of	  degenerating	  neurons-­‐positive	  cells	  at	  days	  7,14,	  and	  21	  (Yu	  
et	  al.,	  2013).	  Both	  drugs	  at	  the	  sub-­‐therapeutic	  levels	  resulted	  in,	  fewer	  side	  effects,	  
improved	  tolerance	  to	  long	  term	  use,	  and	  multiple	  signal	  pathway	  targeting,	  owing	  to	  
the	  diverse	  pathophysiology	  of	  TBI	  (Chiu	  et	  al.,	  2013).	  	   	  
1.6.3	  Neurosteroids	  
Neurosteroids	  are	  steroids	  synthesized	  in	  the	  brain.	  There	  is	  limited	  literature	  regarding	  
neurosteroids	  in	  TBI.	  VanLandingham	  group	  tested	  the	  effect	  of	  a	  neurosteroid	  in	  
model	  of	  CCI	  (VanLandignham	  et	  al.,	  2007).	  	  CCI	  was	  performed	  on	  the	  animals	  and	  
administration	  of	  allopregnanolone	  (ALLO)	  was	  administered	  (8	  mg/kg)	  using	  an	  I.P.	  
dose	  at	  1	  h	  and	  then	  a	  subcutaneous	  dose	  at	  6	  h	  and	  followed	  every	  24hr	  post	  injury.	  
Brains	  were	  collected	  at	  48	  h,	  used	  for	  mRNA	  analysis,	  and	  at	  24	  and	  72	  h	  post-­‐injury	  
for	  protein	  analysis.	  Animals	  treated	  with	  ALLO	  showed	  significantly	  lower	  CD55	  protein	  
expression	  when	  compared	  with	  controls.	  This	  gene	  encodes	  a	  glycoprotein	  in	  the	  
regulation	  of	  the	  complement	  cascade.	  Through	  the	  binding	  of	  this	  encoded	  protein	  to	  
other	  complement	  proteins,	  there	  is	  acceleration	  in	  their	  decay.	  This	  decay	  leads	  to	  a	  
disruption	  of	  the	  cascade	  and	  prevent	  damage	  to	  the	  host	  cells.	  There	  was	  significantly	  
lower	  expression	  of	  the	  CD55	  gene	  in	  vehicle-­‐treated	  injured	  brains,	  compared	  to	  ALLO	  
treatments	  samples.	  Post-­‐injury	  administration	  of	  the	  neurosteroid	  ALLO	  increases	  
CD55	  gene	  expression	  at	  48	  h	  in	  comparison	  to	  the	  vehicle-­‐treated	  TBI	  and	  shams.	  The	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treatment	  maintained	  protein	  expression	  at	  24	  and	  72	  h	  at	  the	  level	  of	  the	  uninjured	  
controls,	  and	  when	  compared	  to	  the	  vehicle-­‐treated	  injured	  brains,	  there	  was	  a	  
significant	  decline	  in	  CD55	  protein	  abundance.	  ALLO	  specifically	  has	  been	  documented	  
to	  reduce	  edema,	  inflammation	  and	  lipid	  peroxidation	  in	  multiple	  models	  of	  brain	  
injury,	  and	  now	  can	  be	  implicated	  in	  the	  control	  of	  expressed	  inflammatory	  mediators	  
through	  the	  CD55-­‐regulated	  mechanism	  (VanLandignham	  et	  al.,	  2007).	  	  
Ganaxolone	  (GX,	  3α-­‐hydroxy-­‐3β-­‐methyl-­‐5α-­‐prengan-­‐20-­‐one)	  is	  the	  3β-­‐methylated	  
analog	  of	  ALLO.	  As	  its	  analog	  compound,	  GX	  is	  a	  positive	  allosteric	  modulator	  of	  GABAA-­‐
benzodiazepine	  receptor-­‐chloride	  ionophore	  complex	  (Carter	  et	  al.,	  1997;	  Nohria	  and	  
Giller,	  2007).	  	  GX	  is	  a	  CNS-­‐selective	  GABAA	  modulator	  that	  has	  well-­‐characterized	  
targets	  in	  the	  brain,	  and	  anxiolytic	  and	  anticonvulsant	  effects.	  The	  compositions	  of	  the	  
GABAA/benzodiazepine	  receptor	  complexes	  are	  altered	  under	  stress-­‐induced	  situations,	  
resulting	  in	  the	  lack	  of	  response	  to	  hallmark	  benzodiazepine	  ligands.	  Additionally	  this	  
receptor	  complex	  is	  involved	  in	  the	  dysfunctional	  productions	  of	  behaviors	  proceeding	  
a	  stress	  or	  traumatic	  event	  are	  well	  published	  in	  both	  preclinical	  and	  clinical	  studies.	  
Studies	  that	  involved	  anxiety	  disorders	  and	  depression	  in	  humans	  showed	  postmortem	  
alterations	  in	  GABAA	  receptor	  binding	  and	  receptor	  subunit	  composition,	  as	  well	  as	  in	  
GABA	  synthesis	  and	  transport	  (Vaiva	  et	  al.,	  2004;	  Geuze	  et	  al.,	  2008).	  This	  synthetic	  
neurosteroid	  exhibited	  effectiveness	  in	  a	  large	  spectrum	  of	  animal	  models	  of	  epilepsy	  
(Gasior	  et	  al.,	  2000;	  Reddy	  and	  Rogawski	  2000	  a,b).	  Powerful	  anti-­‐seizure	  effects	  of	  GX	  
in	  the	  amygdala-­‐kindled	  model	  in	  mice	  support	  the	  use	  of	  this	  substance	  in	  the	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treatment	  of	  temporal	  lobe	  epilepsy,	  and	  according	  to	  Reddy	  and	  Rogawski	  (2009),	  GX	  
treatment	  (7	  mg/kg,	  sc)	  significantly	  reduced	  the	  frequency	  of	  spontaneous	  seizures	  in	  
rats.	  Clinical	  studies	  of	  GX	  have	  shown	  to	  be	  well	  tolerated	  in	  adults	  and	  children.	  In	  
early	  phase	  II	  studies,	  GX	  showed	  to	  be	  beneficial	  in	  adult	  patients	  with	  partial-­‐onset	  
seizures	  and	  in	  epileptic	  children	  with	  a	  history	  of	  infantile	  spasms.	  These	  results	  raise	  
the	  possibilities	  that	  GX	  may	  provide	  a	  specific	  treatment	  for	  TBI	  in	  humans.	  	  
GX	  is	  the	  sole	  neurosteroid-­‐like	  agent	  that	  has	  been	  utilized	  in	  human	  clinical	  trials	  for	  
the	  treatment	  of	  epilepsy	  (Nohria	  et	  al.,	  20010).	  Over	  the	  past	  decade,	  GX	  has	  been	  
used	  in	  varying	  clinical	  trials	  to	  assess	  the	  efficacy	  and	  safety	  in	  the	  treatment	  of	  
epilepsy	  (Laxer	  et	  al.,	  2000)	  In	  a	  recent	  randomized,	  double-­‐blind	  controlled	  study	  a	  
comparison	  of	  GX	  (500	  mg	  t.i.d.)	  to	  placebo	  in	  147	  adults	  with	  partial	  onset	  seizures	  
who	  were	  refractory	  to	  conventional	  antiepileptic	  drugs.	  The	  primary	  endpoint,	  mean	  
weekly	  seizure	  frequency,	  and	  the	  percent	  change	  from	  baseline	  in	  weekly	  seizure	  
frequency	  were	  significantly	  improved	  in	  the	  GX	  group.	  More	  than	  900	  subjects	  have	  
received	  GX	  in	  human	  clinical	  trials;	  where	  common	  treatment-­‐related	  adverse	  events	  
are	  dizziness	  and	  fatigue,	  but	  discontinuation	  rates	  have	  generally	  been	  similar	  to	  that	  
of	  placebo.	  In	  complete,	  GX	  appears	  to	  be	  an	  efficacious,	  well-­‐tolerated	  and	  safe	  






AIMS	  AND	  OBJECTIVES	  
2.1	  Neuroprotection	  Effects	  of	  GX	  
The	  main	  goal	  of	  this	  project	  is	  to	  test	  the	  effectiveness	  of	  a	  novel	  combination	  
neuroprotection	  therapy	  for	  traumatic	  brain	  injury	  (TBI).	  TBI	  affects	  millions	  of	  people	  
worldwide	  every	  year.	  In	  this	  study,	  we	  evaluated	  the	  neuroprotective	  potential	  of	  the	  
neurosteroid	  Ganaxolone	  (GX)	  in	  a	  mouse	  TBI	  model.	  	  GX	  is	  a	  synthetic	  neurosteroid	  
related	  to	  allopregnanolone	  that	  has	  sedative,	  anxiolytic,	  and	  anticonvulsant	  effects.	  To	  
our	  knowledge	  GX	  has	  not	  been	  used	  as	  a	  neuroprotective	  agent	  for	  TBI.	  	  We	  utilized	  a	  
controlled	  cortical	  impact	  (CCI)	  model,	  which	  simulates	  aspects	  of	  concussions,	  brain	  
contusions,	  and	  hemorrhages	  seen	  in	  human	  TBI.	  	  The	  outcomes	  were	  analyzed	  based	  
on	  several	  primary	  protection	  indices	  such	  as	  extent	  of	  neuronal	  injury,	  
neurodegeneration,	  neuroinflammation,	  post-­‐traumatic	  seizures,	  and	  











MATERIALS	  AND	  METHODS	  
3.1	  Animals	  
C57BL/6	  adult	  male	  mice	  (8	  to	  12	  weeks	  of	  age;	  weight	  24-­‐38g)	  were	  housed	  four	  to	  a	  
cage	  with	  free	  access	  to	  food	  and	  water.	  The	  mice	  were	  housed	  in	  an	  environmentally	  
controlled	  animal	  facility	  under	  a	  12-­‐h	  light/dark	  cycle.	  The	  animals	  were	  cared	  for	  
strictly	  in	  compliance	  with	  the	  guidelines	  outlined	  in	  the	  National	  Institutes	  of	  Health’s	  
Guide	  for	  the	  Care	  and	  Use	  of	  Laboratory	  Animals	  (Institute	  of	  Laboratory	  Animal	  
Resources,	  1996).	  All	  animal	  procedures	  were	  approved	  by	  our	  university’s	  Institutional	  
Animal	  Care	  and	  Use	  Committee.	  	  
3.2	  Controlled	  Cortical	  Impact	  Model	  of	  TBI	  
Mice	  were	  anesthetized	  by	  intraperitoneal	  injection	  of	  a	  mixture	  of	  ketamine	  (100	  
mg/kg)	  and	  xylazine	  (10	  mg/kg).	  They	  were	  positioned	  in	  the	  stereotaxic	  frame.	  Once	  
the	  head	  was	  restrained,	  an	  approximate	  5-­‐mm	  craniectomy	  was	  performed	  using	  a	  
portable	  drill	  over	  the	  left	  parietal	  temporal	  cortex	  and	  the	  bone	  flap	  was	  removed.	  
Mice	  were	  subjected	  to	  CCI	  using	  the	  Hatteras	  Pinpoint	  Instrument	  (PCI3000	  Precision	  
Cortical	  Impactor™)	  with	  the	  actuator	  directly	  mounted	  on	  the	  stereotaxic	  instrument	  
(Illustrated	  in	  Fig.2).	  The	  impactor	  3.5	  mm	  tip	  accelerated	  down	  to	  the	  2.00	  mm	  
distance,	  reaching	  a	  preset	  velocity	  of	  4.5m/s,	  and	  the	  applied	  electromagnetic	  force	  
remained	  there	  for	  the	  dwell	  time	  of	  100	  ms,	  and	  then	  retracted	  automatically.	  The	  
contact	  sensor	  indicated	  the	  exact	  point	  of	  contact	  for	  reproducible	  results.	  These	  CCI	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parameters	  lead	  to	  an	  injury	  that	  is	  considered	  to	  be	  severe.	  A	  rounded	  two-­‐channel	  
electrode	  (model	  MS333/1;	  Plastics	  One,	  Roanoke,	  VA)	  was	  stereotaxically	  implanted	  in	  
the	  right	  hippocampus	  (2.9	  mm	  posterior,	  3.0	  mm	  lateral,	  and	  3.0	  mm	  below	  dura)	  
(Franklin	  and	  Paxinos,	  1997)	  and	  anchored	  with	  dental	  acrylic	  to	  three	  jeweler’s	  screws	  
placed	  in	  the	  skull.	  Before	  the	  dental	  cement	  was	  applied,	  a	  small	  plastic	  slip	  was	  
placed	  over	  the	  impact	  zone	  to	  prevent	  the	  dental	  acrylic	  from	  contacting	  the	  brain.	  
Following	  surgery,	  the	  animal	  was	  allowed	  to	  recover	  for	  a	  period	  of	  7	  to	  10	  days.	  	  
The	  experimental	  design	  and	  protocol	  is	  illustrated	  in	  Fig.3.	  Sham	  operated	  mice	  
underwent	  the	  same	  surgical	  procedures	  (craniotomy)	  with	  the	  exception	  of	  the	  
traumatic	  impact.	  For	  the	  first	  2h	  post-­‐CCI,	  mice	  were	  closely	  monitored	  in	  their	  cages.	  
Histopathological	  and	  functional	  outcomes	  were	  compared	  between	  the	  untreated	  
mice	  and	  treated	  mice	  at	  24	  h,	  72	  h,	  7	  d,	  14	  d,	  30	  d,	  60	  d,	  90	  d,	  and	  120	  d	  after	  trauma	  
(2-­‐4	  mice	  per	  time	  per	  experimental	  group).	  Sham	  animals	  were	  tested	  at	  0	  h	  24	  h	  72	  h	  
7	  d	  and	  14	  d.	  	  




	   	  
	  
Figure	  2.	  CCI	  model	  of	  TBI	  in	  mice.	  Hatteras	  Pin-­‐Point	  Instrument	  that	  was	  used	  to	  
perform	  TBI	  and	  the	  stereotaxic	  position	  of	  TBI	  impact	  site,	  anchor	  screws	  and	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3.3	  Brain	  Perfusions	  and	  Histology	  	  
Mice	  were	  anesthetized	  with	  ketamine-­‐xylaxine	  mixture	  and	  transcardially	  perfused	  
with	  4%	  formaldehyde	  solution	  (Fisher	  Scientific)	  in	  sodium	  phosphate	  buffer	  (PB,	  pH	  
7.4).	  Following	  this,	  the	  the	  brain	  was	  carefully	  removed	  from	  the	  skull	  of	  each	  animal	  
and	  post-­‐fixed	  in	  4%	  formaldehyde	  for	  16	  h	  at	  4°C.	  The	  brain	  tissues	  were	  next	  treated	  
with	  PB	  (for	  24	  h),	  10,	  20	  and	  30%	  sucrose	  solution	  in	  PB	  for	  72	  h	  each	  respectively	  and	  
then	  rapidly	  frozen	  with	  O.C.T	  compound	  on	  dry	  ice	  (Rao	  et	  al.,	  2006;	  Kuruba	  et	  al.,	  
2011).	  Serial	  sections	  (30	  μm	  thick)	  were	  cut	  coronally	  through	  the	  forebrain	  containing	  
the	  amygdala	  and	  the	  hippocampus,	  approximately	  from	  bregma	  −0.24	  to	  −7.44	  mm	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(Paxinos	  and	  Watson,	  2007).	  The	  sections	  were	  collected	  serially	  in	  24-­‐well	  plates	  filled	  
with	  PB.	  Every	  10th	  section	  through	  the	  entire	  mouse	  hippocampus	  was	  then	  selected	  
from	  all	  animals.	  Sections	  were	  taken	  at	  300	  μm	  intervals	  and	  processed	  for	  neuronal	  
nuclei	  antigen	  (NeuN,	  total	  neurons),	  parvalbumin	  (PV,	  interneurons)	  and	  Fluoro-­‐jade	  
(FJB,	  degenerating	  neurons)-­‐immunoreactivity.	  
The	  stereology	  system	  consists	  of	  an	  Olympus	  BX53	  microscope	  (Olympus,	  Tokyo,	  
Japan)	  fixed	  with	  a	  DP73	  cooled	  digital	  color	  camera	  (Model:	  DP73-­‐1-­‐51,	  Olympus,	  
Tokyo,	  Japan)	  or	  ORCA-­‐R2	  digital	  CCD	  camera	  (Hamamatsu,	  Hamamatsu	  City,	  Japan)	  for	  
immunofluorescence	  images	  (Figure	  1).	  A	  motorized	  stage	  (Model:	  H101ANNI,	  Prior	  
Scientific,	  Rockland,	  MA,	  USA)	  controlled	  by	  universal	  microscope	  automation	  
controller	  with	  encoder	  (Model:	  500-­‐H31XYZEF,	  ProScan	  III,	  Prior	  Scientific,	  Rockland,	  
MA,	  USA)	  and	  Proscan	  III	  joystick	  (Model:	  P-­‐PS3J100,	  Prior	  Scientific,	  Rockland,	  MA,	  
USA).	  The	  BX53	  microscope	  is	  fixed	  with	  a	  1.25×	  objective	  (PLAPON1.25×,	  numerical	  
aperture	  (NA)	  =	  0.04,	  working	  distance	  (WD)	  =	  5.1	  mm,	  Olympus),	  10×	  objective	  
(UPLSAPO10X2,	  NA	  =	  0.4,	  WD	  =	  3.1	  mm,	  Olympus),	  20×	  objective	  (UPLSAPO20XNA	  =	  
0.75,	  WD	  =	  0.65	  mm,	  Olympus)	  and	  60×	  oil	  immersion	  objective	  (UPLSAPO60XO,	  NA	  =	  
1.35,	  WD	  =	  0.15	  mm,	  Olympus).	  Olympus	  immersion	  oil	  type-­‐F	  (IMMOIL-­‐F30CC,	  
Olympus)	  was	  used	  with	  the	  60×	  oil	  immersion	  objective.	  Appropriate	  cleaning	  supplies	  
are	  kept	  readily	  available	  for	  use	  such	  as	  lens	  cleaning	  solution,	  lens	  paper,	  and	  99%	  
ethanol	  for	  cleaning	  the	  slides.	  The	  stereology	  software	  used	  in	  this	  experiment	  is	  
newCAST	  (Version:	  VIS4.6.1.630,	  Visiopharm,	  Denmark).	  A	  calibration	  slide	  with	  a	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standard	  Visiopharm	  calibration	  grid	  embedded	  on	  the	  glass	  sheet	  in	  the	  center	  is	  
included	  with	  the	  newCAST	  VIS	  software.	  
Super	  images	  of	  the	  entire	  slide	  containing	  hippocampal	  sections	  (three	  slices	  in	  each	  
slide)	  were	  acquired	  by	  stereology	  newCAST	  software	  (Visiopharm,	  Denmark)	  with	  a	  
1.25×	  objective	  on	  the	  Olympus	  BX53	  microscope.	  Before	  cell	  counting,	  the	  
hippocampus	  was	  delineated	  into	  a	  single	  region	  of	  interest,	  which	  contained	  the	  
dentate	  gyrus,	  dentate	  hilus,	  and	  cornu	  ammonis	  regions	  I-­‐III.	  Neuronal	  density	  was	  
performed	  on	  the	  hemisphere	  of	  the	  brain,	  which	  had	  received	  the	  craniotomy	  and	  TBI	  
incident.	  Tissue	  volume	  was	  calculated	  using	  an	  application	  in	  the	  NewCast	  software	  
that	  combined	  Cavalieri’s	  theory	  and	  vertical	  sectioning.	  To	  produce	  an	  accurate	  
volume	  estimate	  using	  the	  application,	  at	  least	  200	  points	  are	  required	  to	  be	  counted	  
within	  the	  region	  of	  interest.	  Crosshairs	  in	  groups	  of	  3X3	  were	  overlayed	  onto	  the	  
computer	  image	  of	  the	  slide	  and	  appeared	  as	  a	  guide	  for	  the	  volume	  calculation.	  
Volumes	  for	  slides	  were	  calculated	  using	  the	  10X	  objective	  lens.	  After	  the	  volume	  is	  
found	  for	  the	  hippocampus,	  cell	  density	  calculations	  are	  performed	  using	  a	  separate	  
application	  in	  the	  newcast	  software.	  	  
Because	  of	  the	  nature	  of	  TBI,	  the	  stereology	  procedures	  were	  performed	  on	  the	  
hippocampus	  as	  a	  whole,	  rather	  than	  divided	  up	  into	  5	  regions.	  In	  many	  cases	  with	  this	  
experiment,	  the	  TBI	  was	  chronic/severe	  and	  sections	  of	  tissue	  were	  missing	  and/or	  too	  
damaged	  to	  perform	  stereology.	  Because	  of	  this,	  volumes	  between	  control	  and	  TBI	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animals	  were	  compared	  to	  find	  how	  much	  tissue	  was	  lost	  due	  to	  injury—and	  cell	  
density	  counts	  were	  performed	  in	  the	  same	  manner.	  
3.4	  Motor	  Function	  
We	  used	  two	  different	  motor	  function	  tests:	  (1)	  Rota-­‐rod	  test	  and	  (2)	  inverted	  screen	  
test.	  	  
3.4.1	  Rota-­‐Rod	  Test	  	  
The	  ability	  of	  a	  rodent	  to	  maintain	  balance	  and	  keep	  pace	  with	  a	  rotating	  rod	  has	  been	  
used	  in	  varying	  degrees	  of	  success	  in	  the	  past	  decade	  to	  assess	  motor	  function.	  The	  
intent	  of	  this	  test	  is	  to	  subject	  the	  mouse	  to	  walking	  on	  a	  rotating	  rod	  of	  fixed	  diameter	  
at	  a	  maintained	  speed	  over	  a	  predetermined	  period	  of	  time	  unto	  the	  animal	  can	  no	  
longer	  maintain	  its	  position.	  The	  rota-­‐rod	  apparatus	  used	  in	  this	  study	  consisted	  of	  a	  
central	  drive	  rod	  connected	  to	  a	  stepper	  motor	  (IITC	  Life	  Science	  Instrument)	  that	  was	  
divided	  into	  five	  separate	  testing	  stations.	  The	  speed	  at	  which	  the	  rod	  rotated	  can	  be	  
accelerated	  up	  from	  0	  rmp	  to	  over	  40	  rpm	  over	  a	  set	  time	  period.	  	  
Mice	  that	  suffered	  from	  a	  traumatic	  injury	  were	  tested	  on	  the	  rota-­‐rod	  24	  hours	  
following	  the	  surgical	  procedure.	  The	  apparatus	  was	  set	  at	  a	  specific	  acceleration	  of	  5	  
rpm	  over	  60	  sec.	  This	  was	  maintained	  as	  a	  good	  standard	  for	  young	  adult	  mice,	  
although	  it	  should	  be	  noted	  that	  juvenile	  and	  older	  animals	  performed	  poorly	  during	  
this	  task.	  Five	  mice	  were	  placed	  on	  the	  rota-­‐rod,	  one	  per	  testing	  station,	  and	  then	  the	  
timer	  and	  rotating	  rod	  was	  initiated.	  Our	  model	  came	  equipped	  with	  a	  timer	  that	  began	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when	  the	  protocols	  were	  set	  and	  stopped	  when	  the	  animal	  fell	  to	  the	  floor	  of	  the	  
apparatus,	  as	  was	  detected	  through	  a	  weight	  sensor.	  The	  mouse	  is	  required	  to	  walk	  
continually	  in	  a	  stationary	  position.	  The	  latency	  to	  fall	  from	  the	  rotating	  rod	  was	  
determined	  and	  taken	  as	  a	  measure	  of	  motor	  function.	  
Although	  locomotor	  testing	  has	  its	  skeptics,	  changes	  in	  any	  behavior	  can	  elucidate	  
critical	  information	  in	  the	  diagnoses	  of	  neurological	  deficits.	  Brain	  injury	  models	  
employed	  by	  many	  researchers	  can	  produce	  subtle	  or	  often	  pronounced	  alterations	  in	  
motor	  behavior.	  However,	  these	  animal	  models	  are	  not	  devoid	  of	  drawbacks,	  which	  
include	  profound	  changes	  in	  motor	  function	  that	  can	  muddle	  the	  interpretations	  of	  the	  
behavioral	  results.	  Therefore,	  it	  is	  critical	  for	  neuroscientist	  to	  be	  conscious	  of	  and	  to	  
characterize	  these	  changes	  carefully.	  The	  following	  examines	  several	  methods	  for	  
assessing	  motor	  and	  exploratory	  functions	  in	  the	  TBI	  mouse	  model.	  	  
Locomotor	  and	  exploratory	  behavior	  may	  additionally	  be	  skewed	  by	  several	  other	  
factors	  such	  as	  time	  of	  day	  (mice	  are	  generally	  nocturnal	  animals	  and	  are	  significantly	  
more	  active	  during	  dark	  periods);	  anxiety	  (animals	  may	  or	  may	  not	  be	  more	  active	  
dependent	  on	  what	  situation	  they	  are	  exposed	  to);	  state	  of	  wakefulness	  or	  arousal;	  
motivation;	  age;	  general	  health;	  and	  genetic	  strain.	  All	  of	  these	  factors	  require	  detailed	  
experimental	  designs	  and	  it	  is	  therefore	  prudent	  to	  control	  for	  these	  and	  maintain	  
consistency	  from	  the	  outset.	  However,	  natural	  variations	  in	  activity	  and	  stress	  levels	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more	  often	  than	  not	  exist	  between	  mice	  of	  the	  same	  strain	  despite	  controlling	  for	  all	  
the	  factors.	  Thus,	  group-­‐sizes	  that	  will	  balance	  out	  the	  statistical	  analysis	  are	  required.	  
3.4.2	  Screen	  Test	  	  
For	  all	  tests,	  the	  mice	  were	  brought	  to	  the	  experimental	  room	  5-­‐20	  minutes	  before	  
testing	  to	  ensure	  arousal.	  Mice	  were	  returned	  to	  the	  home	  cage	  after	  each	  motor	  test	  
to	  permit	  recovery	  of	  muscle	  strength.	  Evaluation	  for	  motor	  impairment	  was	  carried	  
out	  using	  an	  inverted	  screen	  test	  that	  determines	  an	  animal’s	  ability	  to	  support	  its	  own	  
body	  weight	  by	  grasping	  a	  grid	  (Coughenour	  et	  al.,	  1977).	  Mice	  (n=14/group)	  were	  
placed	  on	  a	  horizontal	  metal	  grid	  (consisting	  of	  1.5-­‐mm-­‐diameter	  rods	  situated	  1	  cm	  
apart),	  which	  was	  then	  inverted	  and	  suspended	  roughly	  45	  cm	  above	  their	  home	  cage.	  
The	  latency	  that	  the	  mouse	  remained	  on	  the	  grid	  was	  measured.	  Animals	  that	  fell	  from	  
the	  grid	  within	  10s	  were	  scored	  as	  positive	  for	  motor	  impairment.	  	  
Falling	  between	  1-­‐10	  sec	  =	  1	  Falling	  between	  11-­‐15	  sec	  =2	  Falling	  between	  26-­‐60	  sec	  +	  
3	  Falling	  after	  60	  sec	  =	  4.	  	  
3.5	  Elevated-­‐Plus	  Maze	  
The	  elevated	  plus	  maze	  test	  is	  one	  of	  the	  most	  widely	  used	  tests	  for	  measuring	  anxiety-­‐
like	  behavior.	  The	  test	  is	  validated	  on	  the	  natural	  aversion	  response	  of	  mice	  for	  open	  
and	  elevated	  areas,	  and	  additionally	  on	  their	  natural	  spontaneous	  exploratory	  behavior	  
in	  novel	  environments.	  The	  apparatus	  consists	  of	  open	  arms	  and	  closed	  arms,	  crossed	  
in	  the	  middle	  perpendicularly	  to	  each	  other,	  and	  a	  center	  area.	  Mice	  are	  allowed	  access	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to	  all	  of	  the	  arms	  and	  are	  permitted	  to	  move	  freely	  between	  them.	  The	  number	  of	  
entries	  into	  the	  open	  arms	  and	  the	  time	  spent	  in	  the	  open	  arms	  are	  used	  as	  indices	  of	  
open	  space-­‐induced	  anxiety	  in	  mice.	  	  
The	  apparatus	  used	  for	  the	  elevated	  plus	  maze	  test	  is	  comprised	  of	  two	  open	  arms	  
(25x5x0.5	  cm)	  across	  from	  each	  other	  and	  perpendicular	  to	  two	  closed	  arms	  (25x5x16	  
cm)	  with	  a	  center	  platform	  (5x5x0.5	  cm).	  The	  open	  arms	  have	  no	  walls,	  whereas	  the	  
closed	  arms	  have	  high	  (16	  cm)	  walls	  to	  enclose	  the	  arms.	  The	  entirety	  of	  the	  apparatus	  
is	  50	  cm	  above	  the	  floor	  and	  is	  placed	  in	  an	  empty	  circular	  tank	  (100	  cm	  diameter,	  35	  
cm	  tall;	  and	  is	  normally	  used	  for	  the	  Morris	  water	  maze	  task)	  to	  protect	  the	  mice	  that	  
fall	  or	  attempt	  to	  escape	  during	  the	  experiment.	  The	  apparatus	  is	  made	  of	  black	  glossy	  
plexi-­‐glass.	  
Mice	  were	  housed	  with	  a	  12-­‐h	  light/dark	  cycle.	  Behavioral	  testing	  was	  performed	  
between	  9:00	  AM	  and	  6:00	  PM.	  All	  the	  experimental	  mice	  were	  transferred	  to	  the	  
behavior	  testing	  room	  30	  min	  prior	  to	  beginning	  the	  first	  trial.	  The	  behavior	  testing	  
rooms	  is	  soundproof	  and	  the	  illumination	  level	  is	  maintained	  at	  an	  appropriate	  lux.	  A	  
mouse	  is	  placed	  in	  the	  center	  area	  of	  the	  maze	  with	  its	  head	  directed	  toward	  a	  closed	  
arm.	  The	  number	  of	  entries	  (an	  entry	  is	  defined	  as	  the	  center	  of	  mass	  of	  the	  mouse	  
entering	  an	  arm)	  into	  each	  arm	  and	  the	  time	  spent	  in	  each	  of	  the	  arms	  are	  recorded	  
and	  serve	  as	  indices	  for	  measuring	  anxiety-­‐like	  behavior.	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Mice	  were	  permitted	  to	  move	  uninhibited	  about	  the	  maze	  for	  5	  min.	  Each	  mouse	  
received	  three	  trials-­‐one	  before	  surgery,	  one	  7	  days	  post-­‐surgery,	  and	  the	  final	  one	  14	  
days	  post-­‐surgery.	  	  The	  number	  of	  entries	  into	  each	  arm,	  the	  time	  spent	  in	  each	  arm,	  
and	  the	  percentage	  of	  entries	  into	  the	  open	  arms	  were	  calculated.	  Following	  each	  trial,	  
all	  arms	  and	  the	  center	  area	  was	  cleaned	  with	  70%	  isopropyl	  alcohol.	  This	  served	  to	  
eradicate	  odor	  and	  served	  to	  prevent	  a	  bias	  based	  on	  olfactory	  cues,	  thus	  allowing	  for	  
the	  conduction	  of	  tests	  under	  controlled	  conditions.	  
Infrequently	  (in	  less	  than	  1%	  of	  mice	  tested),	  mice	  run	  to	  the	  edge	  of	  the	  open	  arms	  
and	  fall	  off.	  When	  this	  occurred,	  the	  mouse	  was	  rapidly	  picked	  up	  and	  placed	  back	  onto	  
the	  open	  arms	  of	  the	  maze.	  This	  behavior	  was	  recorded	  on	  the	  data	  sheet	  and	  taken	  
into	  consideration	  when	  the	  behavioral	  data	  was	  analyzed.	  Behavioral	  data	  from	  an	  
animal	  that	  does	  this	  would	  usually	  be	  excluded	  from	  analysis,	  however	  due	  to	  the	  
nature	  of	  our	  study	  the	  animal’s	  data	  was	  still	  used.	  If	  freezing	  were	  to	  occur	  due	  to	  a	  
noise	  or	  movement,	  a	  note	  was	  taken	  on	  the	  data	  sheet	  and	  considered	  an	  anomaly	  if	  it	  
was	  an	  extended	  period	  of	  time	  (more	  than	  100s	  on	  the	  open	  arm),	  and	  was	  deemed	  
an	  exclusion	  criteria.	  However,	  the	  animal	  was	  then	  tested	  as	  a	  later	  date	  to	  be	  
commensurate	  with	  other	  animals	  in	  its	  cohort.	  	  
3.6	  Assessment	  of	  Cerebral	  Edema	  
Brain	  water	  content,	  a	  sensitive	  measure	  of	  cerebral	  edema,	  was	  quantified	  using	  the	  
wet-­‐dry	  method	  (Dempsey	  et	  al.,	  2000;	  Hewett	  et	  al.,	  2006).	  At	  24h	  and	  72h	  post-­‐
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injury,	  time	  points	  associated	  with	  significant	  edema	  formation	  following	  experimental	  
TBI	  (Kiening	  et	  al.,	  2002),	  brain	  water	  content	  was	  estimated	  in	  a	  3	  mm	  coronal	  tissue	  
section	  of	  the	  ipsilateral	  and	  contralateral	  cortex	  regions	  of	  the	  brain	  centered	  on	  the	  
impact	  site.	  Whole,	  fresh	  brain	  was	  weighed	  using	  weigh-­‐paper,	  dried	  for	  72	  hours	  at	  
57	  degrees	  Celsius	  in	  a	  Thermo	  Scientific	  oven	  and	  reweighed	  to	  obtain	  a	  dry	  weight.	  
Brain	  water	  content	  was	  defined	  as	  %	  of	  water	  calculated	  as	  (wet	  weight-­‐dry	  weight)/	  
(wet	  weight)	  x	  100.	  Additional	  equations	  used	  were	  Water	  content	  =	  (wet	  weight	  –	  dry	  
weight)/dry	  weight	  and	  %Tissue	  swelling	  =	  100*(final	  wet	  weight	  –	  initial	  wet	  
weight)/initial	  wet	  weight.	  	  
3.7	  Neurological	  Motor	  Function	  
The	  composite	  neuroscore	  test	  was	  assessed	  at	  24h,	  72h,	  7d,	  14d,	  21d,	  30d,	  60d,	  90d,	  
and	  120d	  post-­‐injury	  using	  seven	  4-­‐point	  tests	  (maximal	  composite	  neuroscore	  =	  28).	  
Animals	  were	  scored	  on	  a	  4	  (normal)	  to	  0	  (severely	  impaired)	  integral	  scale	  for	  left	  and	  
right	  forelimb	  flexion,	  left	  and	  right	  lateral	  pulsion,	  left	  and	  right	  hind	  limb	  flexion	  and	  
the	  aptitude	  to	  stand	  on	  an	  inclined	  angle	  board	  in	  the	  horizontal	  and	  vertical	  positions.	  	  
3.8	  EEG	  Analysis	  
For	  continuous	  EEG	  recordings,	  two	  surface	  electrodes	  (cortex	  and	  cerebellum)	  and	  a	  
depth	  electrode	  in	  the	  hippocampus	  was	  implanted	  (4mm	  AP.	  2.3mm	  ML.	  3.4mm	  deep	  
of	  DV)	  in	  the	  mice	  directly	  following	  the	  TBI	  event.	  Mice	  were	  then	  allowed	  to	  recover	  
for	  7-­‐10	  days.	  Once	  this	  recovery	  period	  was	  over	  the	  animals	  were	  placed	  into	  single	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house	  cages,	  connected	  to	  an	  apparatus	  to	  record	  EEG	  data	  via	  the	  hippocampus	  
electrode.	  The	  electrographic	  activity	  of	  the	  TBI-­‐induced	  seizures	  was	  defined	  as	  the	  
appearance	  of	  large	  amplitude	  repetitive	  discharges	  (>0.5	  Hz	  with	  at	  least	  double	  the	  
amplitude	  of	  the	  baseline).This	  activity	  was	  acquired	  from	  the	  hippocampal	  electrode	  
using	  pClamp	  10	  	  software	  2.0KHZ	  sample	  rate,	  with	  Digidata	  1322A	  interface	  
(Molecular	  Devices)	  through	  a	  Grass	  CP511	  preamplifier	  (Astro-­‐Med).	  This	  system	  (up	  
to	  sixteen	  channels)	  allowed	  simultaneous	  monitoring	  and	  recording	  of	  animal	  behavior	  
with	  high	  resolution	  video	  (1920x1080	  pixels)	  and	  electrographic	  activity	  in	  awake,	  
freely	  behaving	  mice,	  that	  have	  free	  access	  to	  water	  and	  food.	  Behavioral	  seizures	  
(Video	  EEG	  recordings)	  were	  rated	  according	  to	  Racine’s	  scale	  (Racine,	  1972)	  as	  
modified	  for	  the	  mouse:	  stage	  0,	  no	  response	  or	  behavioral	  arrest;	  stage	  1,	  chewing	  or	  
facial	  twitches;	  stage	  2,	  chewing	  and	  head	  nodding;	  stage	  3,	  forelimb	  clonus;	  stage	  4,	  
bilateral	  forelimb	  clonus	  and	  rearing;	  stage	  5,	  falling.	  At	  the	  end	  of	  the	  study,	  mice	  were	  
anesthetized	  and	  perfused	  transcardially	  with	  paraformaldehyde	  for	  Nissl	  staining	  to	  










CCI	  injury	  to	  the	  lateral	  cortex	  causes	  focal	  brain	  injury	  is	  highly	  associated	  with	  a	  
number	  of	  contusion	  injuries	  that	  include	  intra-­‐parenchymal	  petechial	  hemorrhages.	  
Such	  hemorrhages	  are	  followed	  closely	  in	  incidence	  by	  epidural	  and	  subdural	  
hematomas	  (see	  Fig.4A).	  Our	  histological	  analysis	  showed	  large	  lesions	  in	  the	  cortical	  
gray	  matter,	  as	  well	  as	  axonal	  injury	  in	  the	  adjacent	  white	  matter,	  corpus	  callosum,	  and	  
capsula	  interna	  (Fig.4B).	  In	  addition,	  there	  were	  areas	  of	  degenerations	  in	  the	  cortex,	  
hippocampus	  and	  thalamus.	  Such	  anatomical	  changes	  are	  associated	  with	  a	  spectrum	  
of	  cognitive	  and	  motor	  deficits	  (Thompson	  et	  al.,	  2005).	  Recently	  Hunt	  et	  al.	  showed	  
that	  CCI-­‐induced	  TBI	  in	  the	  lateral	  cortex	  would	  trigger	  the	  development	  of	  PTE	  in	  CD1	  
mice.	  Behavioral	  seizures	  were	  seen	  in	  20%	  of	  animals	  with	  mild	  injury	  and	  in	  36%	  with	  
severe	  injury	  42-­‐71	  days	  post-­‐injury.	  Our	  data	  also	  showed	  increased	  occurrences	  of	  
electrographic	  spontaneous	  seizures	  after	  lateral	  CCI	  injury	  in	  C57BL/6	  mice.	  	  
4.1	  TBI-­‐Induced	  Brain	  Injury	  (Histology)	  	  	  
Nissl	  staining	  was	  performed	  on	  an	  8-­‐12	  week	  old	  C57BL/6	  male	  mouse	  brain	  that	  had	  
received	  a	  severe	  TBI	  using	  the	  CCI	  model	  (Fig.1B).	  A	  visible	  cavity	  can	  be	  seen	  
extending	  into	  the	  hippocampus	  layer.	  This	  severe	  TBI	  event	  showed	  amplified	  
distortions	  and	  cranial	  swelling	  post-­‐impact,	  where	  the	  hippocampal	  and	  cortical	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regions	  on	  the	  ipsilateral	  side	  are	  completely	  gone.	  We	  used	  this	  CCI	  model	  to	  
determine	  the	  effects	  of	  severe	  TBI	  through	  the	  measurements	  of	  tissue	  deformation,	  




(A) TBI	  brain	   (B) TBI	  Nissl	  stained	  section	  
	   	  
	   	  
Figure	  4.	  TBI	  impacted	  brain.	  (A)	  Sample	  CCI	  mouse	  brain	  representative	  of	  TBI	  injury	  to	  







4.2	  Effect	  of	  GX	  on	  TBI-­‐Induced	  Rota-­‐Rod	  Motor	  Impairment	  
We	  examined	  the	  motor	  ability	  of	  the	  mice	  of	  all	  three	  groups	  (Sham,	  Control,	  and	  GX	  
treated)	  with	  the	  rota-­‐rod	  task.	  As	  shown	  in	  Figure	  5,	  all	  of	  the	  mice	  in	  the	  Sham	  group	  
were	  able	  to	  stay	  for	  the	  maximum	  time	  (60s)	  on	  the	  stationary	  rod	  in	  the	  pre-­‐sessions.	  
The	  majority	  of	  the	  Control	  mice	  were	  unable	  to	  stay	  on	  the	  stationary	  rod.	  The	  GX	  
mice	  mirrored	  the	  Sham	  mice.	  The	  effect	  of	  Sham	  surgery,	  Control	  mice	  and	  GX	  treated	  
mice	  on	  time	  spent	  on	  the	  rotating-­‐rod	  is	  shown	  below	  in	  Fig.5.	  Control	  mice	  showed	  
no	  significant	  improvement	  over	  the	  course	  of	  the	  14d	  period,	  while	  the	  GX	  mice	  
exhibited	  a	  significantly	  increased	  performance	  over	  the	  14d-­‐testing	  period.	  Because	  of	  
these	  pronounced	  deficits,	  it	  would	  be	  unwise	  to	  conduct	  cognitive	  experiments	  with	  a	  
significant	  motor	  component	  (e.g.,	  Morris	  water	  maze)	  during	  this	  time	  period.	  It	  can	  
be	  concluded	  that	  mice	  treated	  with	  GX	  showed	  improved	  functional	  motor	  function	  





































4.3	  Effect	  of	  GX	  on	  TBI-­‐Induced	  Screen	  Test	  Motor	  Impairment	  
The	  screen	  test	  was	  used	  to	  measure	  grip	  strength	  in	  controlled	  versus	  GX	  treated	  
mice.	  Our	  data	  was	  collected	  at	  1d,	  3d,	  7d,	  and	  14d,	  although	  preliminary,	  showed	  that	  
mice	  treated	  with	  GX	  exhibited	  increased	  latency	  to	  fall	  over	  a	  period	  of	  time	  (Fig.6).	  
Thus	  it	  can	  be	  concluded	  that	  mice	  treated	  with	  GX	  remained	  longer	  on	  the	  grid	  when	  
compared	  to	  control	  mice.	  Additionally	  when	  compared	  to	  Sham	  mice,	  the	  GX	  treated	  
mice	  were	  almost	  completely	  normalized,	  showing	  little	  neurological	  deficits	  in	  grip	  




































4.4	  Effect	  of	  GX	  on	  TBI-­‐Induced	  Sensory	  Motor	  Functional	  Impairment	  
The	  composite	  neuroscore	  data	  assessed	  neurological	  deficits	  in	  our	  Control	  mice	  but	  
showed	  no	  significant	  deficit	  in	  mice	  that	  were	  treated	  with	  GX	  (Fig.7).	  The	  average	  was	  
taken	  of	  the	  scores	  and	  a	  significant	  difference	  was	  found	  between	  the	  treated	  group	  
and	  the	  control	  animals.	  Additionally,	  the	  neuroscore	  analysis	  suggests	  normalization	  
between	  the	  Sham	  animal	  scores	  and	  the	  scores	  of	  the	  GX	  treated	  group.	  	  We	  can	  
43	  
	  
conclude	  that	  animals	  treated	  with	  GX	  showed	  improvements	  in	  neurological	  scores	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4.5	  Effect	  of	  GX	  on	  TBI-­‐Induced	  Brain	  Edema	  
Brain	  edema	  has	  been	  a	  TBI	  target	  for	  decades	  now	  and	  is	  identified	  and	  continuously	  
monitored	  in	  TBI	  patients	  through	  imaging,	  clinical	  exams,	  and	  intracranial	  pressure	  
monitoring.	  Cerebral	  edema	  causations	  are	  cytotoxicity,	  and	  vasogenic-­‐	  resulting	  from	  
a	  disruption	  in	  the	  blood-­‐brain	  barrier	  (BBB).	  As	  shown	  in	  Tables	  1-­‐3,	  our	  results	  
indicates	  that	  animals	  treated	  with	  GX	  and	  Sham	  animals	  had	  significantly	  lower	  edema	  
in	  both	  the	  percent	  Brain	  water	  content	  and	  the	  water	  content	  (g/g	  dry	  weight),	  while	  
the	  non-­‐treated	  animals	  had	  significantly	  increase	  percent	  changes	  in	  both	  the	  Brain	  
water	  content	  and	  the	  dry	  weight	  comparisons.	  Additionally,	  our	  data	  showed	  a	  
significant	  difference	  between	  the	  percentage	  of	  brain	  swelling	  in	  Sham	  and	  injured	  
animals,	  but	  no	  significant	  difference	  between	  Sham	  and	  GX	  treated	  animals	  (Table	  1-­‐
3).	  These	  results	  suggest	  that	  tissue	  swelling	  was	  reduced	  in	  GX	  treated	  animals	  and	  by	  









Table	  1.	  Brain	  edema	  analysis.	  Measurements	  of	  %	  brain	  water	  content	  and	  %	  change	  
between	  groups.	  
Model	  CCI	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  %	  Brain	  water	  content	   	  
	   Non-­‐Injured	  
(Sham)	  






Contralateral	  	   38%	   76.69%	   60%	   39%	   22%	  
Ipsilateral	   45%	   76.07%	   56%	   31%	   11%	  
Contralateral	   53%	   76.8%	   60%	   24%	   7%	  
Ipsilateral	   56%	   77.9%	   58%	   22%	   2%	  
	  
Table	  2.	  Brain	  edema	  analysis.	  Measurement	  of	  the	  water	  content	  for	  the	  g/g	  dry	  
weight	  and	  the	  %	  change	  between	  groups.	  
Model	  CCI	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  Water	  content	  (g/g	  dry	  weight)	   	   	  
	   Non-­‐Injured	  
(Sham)	  






Contralateral	   0.83	   3.17	   1.26	   282%	   51.8%	  
Ipsilateral	   1.13	   3.29	   1.5	   191%	   32.7%	  
Contralateral	   1.28	   3.3	   1.39	   158%	   8.9%	  
Ipsilateral	   0.615	   3.53	   1.52	   474%	   147%	  
	  
Table	  3.	  Brain	  edema	  analysis.	  Measurement	  of	  the	  brain	  swelling	  %	  change	  between	  
groups.	  
Model	  CCI	   Brain	  Swelling	  %	  Change	  
Non-­‐Injured	  Sham	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.19%	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.05%	  
Injured	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.203%	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.23%	  
Injured	  (GX	  Treated)	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  0.18%	  






4.6	  Effect	  of	  GX	  on	  TBI-­‐Induced	  Plus-­‐Maze	  Anxiety	  Behavior	  
In	  this	  study,	  we	  tested	  CCI	  Control	  injured	  mice	  and	  CCI	  injured	  GX	  treated	  mice	  in	  the	  
elevated-­‐plus	  maze	  7d	  and	  14d	  post-­‐injury,	  which	  is	  described	  in	  detail	  above,	  to	  
investigate	  the	  anti-­‐anxiety	  effects	  of	  TBI.	  The	  results	  we	  have	  obtained	  using	  the	  
elevated	  plus	  maze	  to	  determine	  the	  effects	  TBI	  are	  robust	  and	  replicable.	  As	  shown	  in	  
Figure	  8,	  we	  found	  that	  following	  a	  traumatic	  brain	  event,	  a	  significantly	  increased	  time	  
was	  spent	  on	  the	  open	  arms	  of	  the	  plus	  maze	  of	  the	  Control	  mice	  when	  compared	  to	  
GX	  and	  Sham	  treated	  mice.	  Thus,	  we	  can	  conclude	  that	  a	  traumatic	  event	  in	  Control	  
mice	  caused	  a	  dis-­‐inhibition	  behavior	  in	  the	  elevated	  plus	  maze	  test,	  which	  was	  not	  


































Figure	  8.	  Effects	  of	  GX	  on	  TBI-­‐Induced	  plus	  maze	  anxiety	  measuring	  time	  spent	  on	  the	  




4.7	  TBI-­‐Induced	  Epilepsy	  Development	  in	  a	  Control	  CCI	  Group	  
One	  of	  the	  major	  parts	  of	  epilepsy	  in	  regards	  to	  the	  pathophysiology	  is	  epileptogenesis,	  
where	  a	  normal	  brain	  can	  become	  progressively	  epileptic	  due	  to	  injury	  factors.	  In	  this	  
study,	  it	  was	  our	  goal	  to	  generate	  epileptogenic	  mice	  following	  a	  traumatic	  Injury	  
event.	  	  The	  progression	  of	  spontaneous	  seizures	  is	  illustrated	  in	  Fig.9.	  	  Figure	  10	  shows	  
two	  sample	  spontaneous	  recurring	  seizure	  (SRS)	  EEG	  events	  in	  two	  of	  our	  Control	  mice	  
and	  a	  bar	  chart	  outlining	  the	  average	  number	  of	  seizures	  per	  day	  for	  120d	  period	  in	  our	  
control	  group.	  The	  first	  emergent	  (SRS)	  in	  this	  control	  group	  was	  seen	  at	  day	  21	  (Fig.9).	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This	  was	  an	  unexpected	  result,	  in	  that	  the	  majority	  of	  the	  literature	  hadn’t	  shown	  any	  
type	  of	  seizure	  activity	  until	  around	  day	  60.	  What	  was	  expected	  was	  the	  increase	  in	  
seizure	  number	  per	  day	  and	  the	  clustering	  of	  the	  events.	  Our	  results	  show	  a	  relatively	  
steady	  increase	  in	  the	  number	  of	  seizures	  per	  day	  in	  the	  control	  group,	  adhering	  to	  the	  
published	  data,	  that	  once	  a	  brain	  suffers	  a	  seizure,	  the	  epileptogenesis	  susceptibility	  


































(B) Spontaneous	  seizure	  day	  45	  post-­‐TBI	  
	  
Figure	  10.	  (A)	  &	  (B)	  Representative	  EEG	  traces	  of	  spontaneous	  seizures	  at	  various	  





































This	  study	  was	  the	  first	  effort	  to	  adapt	  the	  CCI	  model	  of	  epileptogenesis	  to	  the	  AED	  
testing	  of	  the	  neurosteroid	  GX,	  and	  it	  is	  separated	  from	  previous	  pre-­‐clinical	  AED	  
studies	  in	  several	  respects.	  First,	  the	  anti-­‐epileptic	  effect	  of	  GX	  has	  never	  been	  
evaluated	  in	  TBI	  patients	  or	  animal	  models.	  Second,	  continuoouse	  seizure	  monitoring	  
by	  EEG	  and	  video	  recordings,	  has	  previously	  not	  been	  reported	  in	  TBI	  CCI	  injury	  models	  
using	  GX	  treatment.	  Finally,	  the	  treatment	  itself	  is	  novel:	  the	  GX	  neurosteroid	  is	  
resistant	  to	  tolerance	  mechanisms	  such	  as	  conversion	  to	  a	  3-­‐keto	  form.	  This	  model	  
system	  yielded	  another	  fortuitous	  result-­‐	  we	  were	  able	  to	  identify	  both	  convulsive	  
seizures	  which	  were	  rare	  but	  lasted	  minutes,	  and	  non-­‐convulsive	  seizures	  which	  were	  
frequent	  but	  lasted	  tens	  of	  seconds.	  To	  our	  knowledge,	  this	  study	  is	  the	  first	  study	  to	  
identify	  both	  seizure	  types	  in	  the	  TBI	  mouse	  model.	  
Our	  study	  established	  a	  mouse	  TBI	  model	  system	  capable	  of	  providing	  anatomic	  
histopathological,	  electroencephalographic,	  and	  behavioral	  outcomes	  as	  a	  means	  to	  
test	  therapies	  for	  this	  disease.	  Specifically,	  herein,	  we	  tested	  the	  use	  of	  GX	  neurosteroid	  
after	  TBI	  and	  derived	  meaningful	  data	  on	  its	  usefulness.	  Our	  experimental	  studies	  to	  
this	  point	  have	  indicated	  a	  potential	  for	  GX	  in	  improving	  the	  behavioral	  and	  functional	  
neurological	  deficits	  observed	  following	  TBI.	  GX	  treated	  animals	  had	  significantly	  
reduced	  brain	  tissue	  swelling,	  improved	  motor	  function	  when	  tested	  on	  the	  rota-­‐rod,	  
improved	  neurological	  deficits	  in	  grip	  strength	  over	  a	  period	  of	  time,	  a	  lack	  of	  dis-­‐
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inhibition	  effects,	  and	  improved	  Neuroscores.	  It	  was	  noted	  that	  animals	  within	  the	  GX	  
edema	  group	  had	  slightly	  less	  tissue	  swelling	  than	  Sham	  animals.	  It	  was	  our	  assessment	  
that	  animals	  in	  the	  Sham	  group	  were	  still	  subjected	  to	  a	  craniectomy,	  and	  thus	  was	  
susceptible	  to	  tissue	  swelling	  as	  well.	  In	  conclusion	  our	  results	  demonstrate	  that	  GX	  has	  
potent	  positive	  effects	  on	  the	  behavior	  associated	  deficits	  and	  edema	  in	  the	  CCI	  mouse	  
model	  and	  considering	  the	  variety	  of	  potential	  mechanisms,	  GX	  may	  prove	  to	  be	  a	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